korea innovative pharmaceutical company directory book

KOREA INNOVATIVE

PHARMACEUTICAL COMPANYDIRECTORY

BOOK

Pharmaceutical

Pharmaceutical

98

Anycough Cap.

For a better life

Ahngook pharm

The 50years old leading R&D oriented Korean pharmaceutical manufacturer/Distributor/Exporting/licensor company.

Mainly focusing on Respiratory/GI/Cardio/NSAID. Nominated as one of the leading innovative R&D company in Korea by governement. A variety of licensing/importing opportunity (New Antitussive/Expectorant, Modified GI modulator/Chiral PPI tablet form, Syrup type Dexibuprofen and so on)Ahngook pharm is the top respiratory field market leader in Korea with Synatura syrup and Anycough cap.Not only Ahngook has been focusing on respiratory syrup but also big market player in Cardiovascular field with Levotension (S-amlodipine tablet). And Ahngook has been launching new and differentiated drugs in the market with strong R&D capability.Ahngook’s financial status is very sound and stable with sound cash flow and profit.Likewise, Ahngook is one of the most promising pharmaceutical company in Korea.

Brief Company Profile

Brief History of AhngookYear Milestones1959 Established1969 Mr. June-Sun Auh joined as President1986 Completion of the Korea GMP Facility1994 Launch of Tobicom_s(Eye-nutrient) / Selected as ‘the HIT product’ of the year1998 Mr. Jin Auh was named CEO & President2000 Launching of Prospan and Listed on KOSDAQ2005 Approval of BGMP synthetic Facility by KOREA FDA2006 Launch of Levotension (the first S-amlodipine in Korea) for the treatment of hypertension

2009Groundbreaking of New GMP facilitiesAhngook’s “Anycough”(Novel Antitussive) was launched in July, 2009Ahngook’s 50th Anniversary ceremony held

2010 Out-licensing of Anycough to Biocopea (UK), June 7th. 2010

2011Launching of Synatura, new herbal formulationCo-Promotion agreement for Zanditen of Novartis KoreaCo-Promotion agreement for Harnal-D(BPH) and Vesicare(OAB) of Astellas Korea

2012 In-licensing of Lupapin & Export MOU of SynaturNominated as ‘the innovative pharmaceutical company’ by Korean Ministry of Health.

· Founded in 1959· Main Business areas : Pharmaceuticals, Diagnostic Medical Devices, Cosmetics and Export· Sales : KRW 121 Bil.(USD 110 M in 2011)· Employees : 471 Persons

· HQs is located in Seoul· Central Reseach Center and General Plant are located in Gyeonggi-do· Representatives - Mr. June-Sun Auh : Chairman - Mr. Jin Auh : CEO & President

CONTACT US

James S.Y.CheonVice President / Global Business Division• Phone : +82-2-3289-4348• Fax : +82-2-849-4123• E-mail : [email protected]

· Company Ahngook pharm.co.Ltd· CEO Jin Auh· Specialty Pharmaceutical Manufacturer, Distributor, Exporter · Location 993-75, Daelimdong, Yongdeungpo, Seoul, Korea· Homepage www.ahn-gook.com

Levotension Tab.

Synatura Syrup

Pharmaceutical

Pharmaceutical

98

Towards Global Standard R&D for Healthcare Products

BCWORLD PHARM

BCWORLD PHARM is a technology-driven pharmaceutical company in Korea whose expertise in formulation and process development enables it to provide quality generics as well as value-added novel formulation products.

BCWORLD PHARM strives to establish its position as a pioneer in developing value-added pharmaceuticals through cutting-edge formulation technology including immediate/controlled release as well as fast-dissolv-ing DDS, combined formulation, gastro-retentive system and depot formulation by way of proactive invest-ments in R&D and strategic alliances.

Recently BCWORLD PHARM not only has been certified as Korea Innovative Pharmaceutical Company (KIPC) by Korea Ministry of Health & Welfare but also designated as Advanced Technology Center (ATC) by Korea Ministry of Knowledge Economy.

Main ProductsTherapeutic Class Products

Antibiotic (Carbapenem) Mepem Inj., Cilacin Inj. etc.Antiinfectives Merogel Gel, BC Itraconazol Tab., etc.Hyperlipidemia Starova Tab., BC Atorvastatin Tab. etc.Anti-Osteoporosis Agents Pamiron Inj., Risidro Tab.Anti-Hypertensives Ibertan Tab., Ibertan Duo Tab., Duomax Tab. etc.GI Agents Mucopid Tab., BC Ranitidine Inj. etc.Narcotics Remiba Inj., BC Morphine Sulfate Inj., BC Fentanyl Inj. etc.

R&D PipelineCategory Item Indications Stage

GRS BCWP_A001 Antibiotic Phase I (Korea)Combination BCWP_C001 Hyperlipidemia PreclinicalMicrosphere BCWP_D001 Anti-cancer FormulationMicrosphere BCWP_D003 Anti-cancer PreclinicalMicrosphere BCWP_D009 Schizophrenia PreclinicalMicrosphere BCWP_D011 Diabetes FormulationSR BCWP_E003 Psychostimulant FormulationSR BCWP_E004 BPH PreclinicalProdrug BCWP_P001 Anti-cancer PreclinicalLiposome BCWP_Y001 Anti-cancer Formulation

CONTACT US

David Kim, DirectorOverseas Business Department• Phone : +82-2-2182-0466• E-Mail : [email protected]• Head Office : 78 Gaepo-ro 22gil

Gangnam-gu, Seoul, Korea

Myung-Kwan Chun, PhD., DirectorResearch Planning Team• Phone : +82-31-628-0921• E-Mail : [email protected]• GRI : A-3, Korea Bio Park,

694-1 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

· Company BCWORLD PHARM. CO., LTD.· CEO Steve H. Hong· Specialty · DDS-oriented Pharmaceutical Company

· Therapeutic categories such as pain, anesthesiology, neurology, and musculoskeletal diseases

· Location 78 Gaepo-ro 22gil Gangnam-gu, Seoul, Korea· Homepage www.bcwp.co.kr

CILACIN INJ.

MEROGEL

PAMIRON INJ.

Pharmaceutical

Pharmaceutical

1110

CONTACT US

Bo Seul (Helen) Noh• Phone : +82-32-850-3259• E-Mail : [email protected]

Since its establishment in 1957, Binex has been dedicated to providing sustainable solutions to healthcare challenges in Korea. Binex is currently comprised of three main business sectors: biologics, chemicals, and cell therapy.

As the only biologics CDMO in Korea, Binex plays the key role in solving the manufacturing bottleneck of biopharmaceutical industry by its hands-on experience on most blockbuster biologics and a top-notch biomanufacturing facility in compliance with the US and EU-GMP regulations. Binex have acquired several biosimilars in our pipeline available for overseas co-business and co-development. We are also looking for biopharmaceutical products to license-in and commercialize within the territory of our expertise.

ProductsProduct Name Indications Status

Human Growth Hormone Growth Hormone Deficiency Currently Marketed

Human Growth Hormone is available in both vial and pen-type cartridge.

R&D PipelineProduct Name Indications Status

Remicade Biosimilar Rheumatoid Arthritis, etc. Phase 1

Remicade is one of the top selling biologics with $8.5 billion in sales in 2011. This monoclonal antibody drug has a broad indication including Rheumatoid Arthritis and other inflammatory conditions. Currently, this Remicade Biosimilar is under clinical phase 1 study with RA patients in both Korea and Japan.

· Company Binex Co., Ltd.· CEO Myoung-Ho Jeong· Specialty Business

Biologics (including biosimilars), chemicals, cell therapy, CDMO (contract development manufacturing organization)

· Location 368-3, Dadae-ro, Saha-gu, Busan, 604-846 Republic of Korea · Homepage http://www.bi-nex.com

Bio Base Camp for biopharmaceutical industry

Binex

Pharmaceutical

Pharmaceutical

1110

CONTACT US

Jei-Wook Chae, Ph.D. , Head of R&D Genomic New Drug Division• Phone : +82-42-930-8573• E-Mail : [email protected]

Bioneer, an innovative biotech company since 1992

Leadership in RNAi Therapeutics:Bioneer Corporation is Korea’s leading biotech company. Bioneer was the first Korean biotechnology company when it was established in 1992. The company has developed state of art molecular biology products and technologies including oligonucleotides/siRNA and instruments of gene manipulation. The company is positioned to fully-integrate its capability to develop next generation technologies in the post-genome era through the invention of new biochemistry and instruments. By capitalizing on the foundational technologies and products developed over 10 years, Bioneer has developed a solid vertically integrated infrastructure to support new higher value-added businesses such as novel RNAi drug development and molecular diagnostics.

Bioneer’s siRNA Drug Development Program using SAMiRNA TechnologySAMiRNA (Self-Assembled-Micelle-inhibitory-RNA) is a novel class of RNAi molecule consisting of RNA, lipid and PEG, which is stable nanoparticle in blood stream and efficient in vivo delivery and finally converted to siRNA in the target cells. SAMiRNA is a SCE (single Chemical Entity), which is manufactured by the proprietary solid-phase synthesis that greatly simplifies the manufacture and QC process relative to other state-of-the-art RNAi delivery platforms. SAMiRNA overcomes major challenges for safe and effective siRNA delivery as well as adverse effects of delivery vehicle. SAMiRNA itself includes its flexibility to incorporate siRNA sequences against any disease target, as well as enhancement of its therapeutic potential as a targeted delivery by the addition of cell-type specific ligands on SAMiRNA. These features and pre-clinical research data suggest that SAMiRNA is the most unique and singularly effective RNAi prodrug system developed to date.

Vertically integrated processes within Bioneer’s siRNA Drug Development Program provide a total solution for siRNA therapeutics discovery and development, from siRNA design/synthesis and preclinical tests to IND filing. With its world-class RNAi core technologies and manufacturing infrastructure, Bioneer is the ideal partner for pharmaceutical and biotechnology companies currently working on the development of RNAi therapeutics, or seeking to enter the RNAi field. Bioneer’s research and technical support teams which have more than 10 year experience ensure top-quality products and developments to meet unmet therapeutic needs.

R&D Pipeline Bioneer is currently advancing clinical development of pipeline programs for previously non-druggable targets, including cancer, COPD, liver fibrosis, and antivirals, internally with our research and development resources as well as through partnerships with major global pharmaceutical companies.

Programs Discovery Development Preclinical Clinical TrialsPhase I Phase II Phase III

BIONEER PROGRAMSSolid Cancers(SAMiRNA-Survivin)

COPDLiver FibrosisAntivirals

PARTNER PROGRAM Liver cancerSANOFI

· Company BIONEER CORPORATION· CEO Han-Oh Park, Ph.D. · Specialty Molecular Diagnostic, Genomic New Drug, Genomic Science,

Synthetic Vaccine· Location 49-3, Munpyeong-dong, Daedeok-gu, Daejeon 306-220, Korea· Homepage www.bioneer.com

A leading biotech company

BIONEER CORPORATION

Pharmaceutical

Pharmaceutical

1312

Since its founding in 1963 Boryung Pharmaceutical Company has been trying its best to contribute to the health and wellbeing of humanity with its’ corporate mission to ‘realize mutual health and co-prosperity based on human centered values.’Boryung has conducted the R&D activities to develop drug substances from a short-term perspective and to develop new drugs for future market from a mid- to long-term perspective. In particular, Boryung Pharmaceutical makes an effort to strengthen the product pipelines in the specialty areas such as cardiovascular drugs, antineoplastics drugs and antibiotics/antiviral. Boryung will devote itself to achieving aspiration of the company which is “Dedicating to the health of Mankind” and becoming a global innovative pharmaceutical company.

ProductsKanarbⓇ (Fimasartan)

Boryung Pharmaceutical has developed Kanarb®, an anti-hypertensive drug that has been approved by the KFDA as the 15th new drug. It is now on sales in Korean market and it has exceeded 10 billion won at the first year of release. Kanarb® is one of the ARBs that are used the most frequently to treat patients with hypertension, it has been developed based on the mechanisms that the blood pressure can be lowered by hinderance of angiotensin to bind type 1 receptor which is involved in the elevation of blood pressure.Until now, Kanarb® had its patent registered in 14 worldwide countries and it was also awarded with Korea Technology Awards by the Ministry of Knowledge Economy and ‘Oh Song New Drug Prize’ by the KFDA in 2011. Boryung is in the process of exporting Kanarb to 13 countries in South America and it is moving to make export deals with China, southeast Asia, the U.S., and Europe, proudly representing Kanarb.

Kanarb combinationKanarb combination is a drug composed of Kanarb (ARB) and diuretics. Boryung recently completed Phase III clinical study and is preparing NDA for launching in 2013.

R&D PipelineTherapeutic area Product RS PC PI PII PIII RG

NCE

CV

BKC 001 ◯

BKC 002 ◯

BKI 001 ◯

BKI 002 ◯

ANBCN 001 ◯

BCI 001 ◯

BCSI 001 ◯

BiologicsBAB 001 ◯

BVN 001 ◯

IMDCNS

BNI 001 ◯

BNT 001 ◯

BNT 002 ◯

GI BGE 001 ◯

CONTACT US

Ji Hyun Min R&D strategic planning • Phone : +82-2-740-4019• E-mail : [email protected]

· Company Boryung Pharmaceutical co., Ltd.· CEO Kwang Ho, Kim· Specialty Full ingredient Pharmaceutical product and substance· Location Boryung Bldg 66-21 Wonnam-dong, Jongro-gu, Seoul· Homepage www.boryung.co.kr

Kanarb

Total Healthcare Company contributing to the human health

BORYUNG Pharmaceutical

Pharmaceutical

Pharmaceutical

1312

To contribute to society through supplying value-added new products to help patients suffering from disease

Bukwang Pharmaceutical Co., Ltd.

CONTACT US

Choi, In AeProduct Development• Phone : +82-2-8288-078 • E-mail : [email protected]

Bukwang Pharmaceutical Co., Ltd. is one of the innovative pharmeceutical companies in Korea and was founded in 1960 with dedication to development and commercialization of novel, outstanding medicines. Bukwang has successfully achieved remarkable growth for over fifty years. Now Bukwang has 520 employees or so, with over 180 billion Korean won of net sales in fiscal year 2010.

Through many years’ efforts, ‘Levovir® cap. (clevudine)’, the 4th drug worldwide for hepatitis B virus, was finally approved by KFDA in 2006, and it is the 11th New Drug developed in Korea. Levovir® was licensed out to Eisai, a Japanese company, and they paid 44 million dollars for the license of clevudine in Asian countries including China.

Bukwang reinvests a part of its profit for continual development of new products. Several projects for developing new medicines are ongoing in the R&D center.

Bukwang will use its novel tools and technologies to attain a prominent market position in the pharmaceutical industry field, increasing its business profitability and the value of the company while providing effective new solutions to incurable diseases and fundamental biological processes.

Products

Levovir® cap.(clevudine) : an innovative new drug for chronic hepatitis B virus)

Levovir was developed by Bukwang and it is the 4th drug developed for HBV infection worldwide, and the 11th new drug in Korea. It is potent in suppression of hepatitis B virus and it has excellent safety and tolerability profiles.

R&D Pipeline

Targeted anti-cancer agent (apatinib mesylate)

- Phase III clinial trial for colorectal cancer and lung cancer completed in China- Phase I/II approved in USA as well as in Korea

Antivirus drug for hepatitis B virus

- Combination drug of clevudine and adefovir dipivoxil to maximize the effectiveness of treatment and to inhibit resistant virus reciprocally- New drug: gained development right for prodrug and exclusive sales rights worldwide from Georgia University, USA.

Novel antivirus drug for Herpes Zoster

- License agreement of a new substance called “L-BHDU”- New synthetic substance collaborated by Georgia and Yale University, USA

Diabetic neuropathy drug

- New drug using only a stereoisomer of thioctic acid- Completed phase III trial

· Company Boryung Pharmaceutical co., Ltd.· CEO Kwang Ho, Kim· Specialty Full ingredient Pharmaceutical product and substance· Location Boryung Bldg 66-21 Wonnam-dong, Jongro-gu, Seoul· Homepage www.boryung.co.kr

· Company Bukwang Pharmaceutical Co., Ltd.· CEO Lee, Sung Koo· Specialty Pharmaceuticals and sanitary aids· Location 398-1, Daebang-dong, Dongjak-gu, Seoul, Korea · Homepage http://www.bukwang.co.kr

Levovir

Pharmaceutical

Pharmaceutical

1514

Celltrion's goal is to provide affordable alternatives to the high-priced antibody drugs, price of which limits broad usage of the drugs.

Celltrion prides itself in being the first company in the world to apply for global regulatory approval of an antibody biosimilar. We are using our accumulated R&D technology and manufacturing capabilities to develop, manufacture and market life changing antibody biosimilars and innovative drugs to patients in need. Celltrion hopes that more suffering patients will be able to have access to and benefit from the new availability of advanced biomedicines.

Products

Celltrion has received approval from the Korean Food and Drug Administration (KFDA) for Remsima (infliximab), which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a) used to treat autoimmune diseases. Remsima is the world's first antibody biosimilar to receive regulatory approval based on global clinical trials. The KFDA approved Remsima for the same indications as the originator, including rheumatoid arthritis, ankylosing spondylities, ulcerative colitis, Crohn's disease, psoriasis. Remsima will also be automatically approved for the treatment of pediatric ulcerative colitis upon completion post marketing surveillance of original drugs. With the approval of Remsima, Celltrion, Inc. has gained entry into the $24 billion TNF-a antagonist market and is likely to be the only biosimilar product in the market for the next 4 to 5 years.

R&D Pipeline

Celltrion currently has 8 biosimilars candidates in various stages of development. The CT-P6 (Breast Cancer) Project is in their most advanced stages of development, successful completion of clinical trials conducted in over twenty countries.

PROJECT CT-P06

- Indication: Metastatic and early breast cancer that over express HER2 gene (Protein Type: mAb)

PROJECT CT-P10

- Indication: Rheumatoid arthritis, Non-Hodgkin’s lymphoma (Protein Type: mAb)

As a company specialized in antibody drug development, Celltrion is also developing innovative antibody drugs to overcome the limitations of existing vaccines and synthetic drugs for pandemic or seasonal influenza viruses. The results of animal tests conducted by the US Center for Disease Control and Prevention showed that this new antibody drug may be effective in treating avian influenza, influenza A and many other variationsof influenza viruses. Thus, this new drug is expected to become the world’s first comprehensive influenza virus treatment antibody, if succeeded.

Additionally, Celltrion is developing innovative drug to cure rabies by collaborrating with the US Center for Disease Control and Prevention. Celltrion is also working with a US biotech company to develop an antibody drug that is expected to be a cure for breast cancer and lung cancer. Other than the antibody drugs pipeline, Celltrion is focusing on developing antibody-drug conjugate that minimizes side effects and maximizes efficacy by inte-grating antibodies with synthetic drug substances. Celltrion’s broad innovative drug pipeline is expected to serve as the driving force behind Celltrion’s future growth.

CONTACT US

Celltrion Headquarters• Phone : +82 32 850 5008• Fax : +82 32 850 5057• E-mail Business : [email protected] Investment : [email protected] Career : [email protected]

· Company Celltrion, Inc.· CEO JungJin Seo· Specialty biopharmaceutical development and manufacture · Location 13-6, Songdo-dong, Yeonsu-gu, Incheon, 406-840, South Korea· Homepage www.celltrion.com

A global technology leader in the field of biosimilar and biologic drug development

Celltrion

Pharmaceutical

Pharmaceutical

1514

CONTACT US

Indy Baik, Team Manager Int’l Sales & Marketing Division• Phone : +82-2-3149-7849• E-Mail : [email protected]

Chong Kun Dang Pharmaceutical Corp. (CKD) was established with the objective of supplying the best quality medicine to the people who need them and performing its business activities for the development of pharmaceutical industry in Korea for over 70 years since its inception in May 1941.

Products

In 1968, CKD obtained US FDA approval for Chloramphenicol, Chloramphenicol palmitate and sterile Chloramphenicol sodium succinate. It was the first commemorative US FDA approval for raw materials in Korean pharmaceutical industry. In addition, CKD has gained additional US FDA approvals of raw materials such as Oxytetracycline hydrochloride, Tetracycline, Rifampicin, Demeclocycline and so on.Since exporting antibiotics to Japan in 1969, CKD has acted as a pioneer of Korean pharmaceutical companies by entering more than 40 overseas markets with the finished products such as Rifampicin, anti-tuberculosis drug.In R&D, CKD was the first company to establish a Research Institute in 1972 among Korean pharmaceutical companies. Through continuous research, CKD had succeeded in the development of many specialty products such as Cipol N®(ciclosporin) and TacroBell®(tacrolimus), immunosuppressive agents for organ transplantations. Such successful developments brought CKD a variety of awards such as Korea Technology Mark and Technology Research Institute Prize.In 2008, CKD’s Lipilou®(atorvastatin), a treatment for high cholesterol was awarded as Korea Technology Gold Prize, and its new formulation and process improvement of atorvastatin were evaluated as Korea’s 10 New Technologies.

R&D Pipeline

CKD has focused on the research and development of new medicines and incrementally modified drugs (IMDs).In the field of new medicines, CKD has developed Camtobell® Injection, CKD's first new chemical entity, and achieved Korea Food & Drug Administration (KFDA) approval for the treatment of small cell lung cancer and ovarian cancer in 2003.CKD is developing a variety of new medicines in broad stages such as CKD-501, oral anti-diabetics under NDA review and CKD-516, anti-cancer drug in phase 1. CKD-501 (lobeglitazone), a potent peroxisome proliferator-activated receptor-y (PPAR-y) agonist, is being developed for the management of type-2 diabetes. Unlike other glitazones, lobeglitazone shows significant safety profile in cardio-toxicity and bladder cancer. Lobeglitazone is likely to be approved by the end of 2012. Furthermore, CKD-732 which was licensed out to Zafgen is being developed as an anti-obesity drug.In case of IMD, CKD is focusing on the development of combination products and the drug delivery system for a new type of oral antibiotics and nanoparticles.In the 21st century, CKD will devote itself to becoming a world-class pharmaceutical company under its motto “Better Life through Better Medicine.” CKD’s great dedication and service will be continued for the welfare of all mankind.

· Company Chong Kun Dang Pharmaceutical Corp.· CEO Jung Woo Kim· Specialty R&D of new medicine and incrementally modified drug (IMD)· Location 368, 3-ga, Chungjeong-ro, Seodaemun-gu, Seoul, Korea · Homepage www.ckdpharm.com

BINT Medicine R&D corporation for terminal illnesses(BINT: Bio-Info-Nano Technology)

Lipilou tab., anti-hyperlipidemic agent

Camtobell inj., anti-cancer agent

Chong Kun Dang

Pharmaceutical

Pharmaceutical

1716

CJ PHARMAToward a No.1 Pharmaceutical Company in KoreaCJ started Pharmaceutical business from 1984, to improve people's quality of life and resume patients' health. In line with CJ's corporate vision, CJ Pharma has been striving for making people healthier, happier and better convenient with innovative and differentiated pharmaceutical products. Now, CJ Pharma has become a representative Korean pharmaceutical company in promising therapeutic areas such as oncology, cardiology, endocrinology and nephrology. CJ Pharma is working hard to grow globally, focusing on rapidly growing China and Southeast Asian markets as well as highly-regulated but attractive Japan and EU markets. Through our newly established cGMP applicable plant in Osong, CJ Pharma can secure global standard manufacturing facilities and operation capabilities. CJ Pharma will make its best efforts to jump into a leading position among global Pharmaceutical Companies.

Products1. Epokine -1stinKoreaand3rdintheworldEpokine®issafeandeffectiveintreatinganemiaofhemodialysispatientswithend-stagerenaldisease2. Leukokine - Leukokine® has the same efficacy and safety with those of the control on neutropenia 3. Vancomycin - Vancomycin® is the best choice for MRSA & MRSE.4. Tapocin - Tapocin® is the first choice for the treatment of MRSA, MRSE and Enterococcus 5. CJ CONDITION - CJ CONDITION has launched in 1992 creating a new market of anti-hangover drink in Korea. 6. Hongsamjin-Gold - Produced with 6-yeared red ginseng with the most outstanding therapeutic effects7. Hutgaesoo (Oriental Rasin Tea) - Hutgaesoo also contains the goodness of 100% arrowroots with its digestive benefits.

Global Business 1. China - Vancomycin Inj./Teicoplanin Inj 2. Japan – Cefotiam , Cefmenoxime, Ceftriaxone inj., Ceftazidime inj. 3. South East Asia - EPO, GCSF, Vancomycin Inj, Tamsulosin, Levofloxacin Inj, Mycophenolate Cyprofloxacin Inj, Amlodipine, Teicoplanin Inj, Simvastatin 4. Africa - EPO 5. Middle East Asia - Ceftriaxone Inj, EPO, Vancomycin Inj 6. Latin America - EPO, Vancomycin Inj, Mycophenolate, Teicoplanin Inj, Topiramate, Donepezil

R&D PipelineProduct Phase Therapeutic AreaCJ-30001 PIII DiabetesCJ-20001 PII GastritisCJ-12420 PI GERD , LicensedCJ-12406 PI H. pylori eradication , LicensedCJ-12433 Pre Clinical Functional Dyspepsia, Licensed

2ndGenerationEPO Pre Clinical Anti-Anemia2ndhGH Pre Clinical Growth Hormone

CONTACT US

Kwang Hee Hong, PhD, MBAHead/Licensing, Pharmaceuticals BU • Phone : +82-2-6740-2181• Mobile : +82-10-3035-7579• E-mail : [email protected]

· Company CJ CheilJedang Corp.· CEO Chul ha Kim· Specialty

BusinessETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology, Nephrology&Urology, Gastro Intestinal, Musculo skeletal, Respiratory, Others), OTC

· Location CJ Cheiljedang Bldg. 292, Ssangrim-dong, Jung-gu, 100-400, Korea· Homepage www.cjp.co.kr

Global Food & Bio Company

CJ CheilJedang

Pharmaceutical

Pharmaceutical

1716

CrystalGenomic Inc., is a leading structural chemoproteiomics-based drug R&D company headquartered in Korea with a US subsidiary for multi-national clinical management (CG Pharmaceuticals, Inc.) in Emeryville, California. CrystalGenomics is devoted in discovery and development of novel therapeutics in the disease areas of great unmet need including inflammation, infectious disease, and oncology.

Products· CG100649

- A novel NSAID for osteoarthritis with tissue-specific mechanism of bypassing problematic tissues (e.g. GI & CV) by binding to carbonic anhydrase enzymes in these tissues and only inhibiting COX-2 enzymes in the desiredtarget tissues (e.g. joints, knees, hips) where carbonic anhydrase is absent.

- Recently completed a Phase IIa study in Europe and Phase IIb study in Korea. - CG100649 is believed to offer both gastrointestinal and cardiovascular safety which has limited the use of

the traditional NSAIDs and COX-2 inhibitors.

· CG400549

- A novel Antibiotic for MRSA & VRSA (in Phase IIa development in USA) - FabI inhibitor - Interrupts fatty acid synthesis process that is only found in bacteria and seems to be an excellent drug candidate

for the “Superbugs”.

· CG200745

- A molecular target cancer therapy agent (in Phase I development in Korea) - This compound targets HDAC and shows superb efficacy so far in its early development stage

R&D PipelineArea Candidate Indication NCE Type Preclinical Ph I Ph II Ph III

NSAID CG100649 Osteoarthritis FIC1

Antibiotic CG400549 MRSA/VRSA FIC, BIC2

Cancer CG200745 Cancer BIC

CONTACT US

Steven Kim, RPh MBA,Director, Business Development• Phone : +82-31-628-2720• E-mail : [email protected]

· Company CrystalGenomice, Inc.· CEO Joong Myung Cho, Ph.D.· Specialty Novel Drug Discovery & Development · Location 5F, Tower A, Korea Bio Park 694-1, Sampyeong-dong, Bundang-gu,

Seongnam-si, Gyeonggi-do, 463-400, Korea· Homepage www.crystalgenomics.com

Clinical stage biotech company with robust pipeline and proven track record in discovery and development of novel drugs

CrystalGenomics

Pharmaceutical

Pharmaceutical

1918

CONTACT US

Hanwoong, Seo 02.6716.1071Paul, Cho 02.6716.1072Serena, Hwang 02.6716.1073

DAE HWA has developed all kinds of medicines ranging from peptic ulcer medicines to preventive and assistant treatments including a cancer, adult related disease etc. We also have a specialty of TDDS (Transdermal Drug Delivery System) patches which are being used in Loxona, Resnalin, Kebanon and etc. DAE HWA established pharmaceutical raw material synthesizing facilities and a plant of CGMP level in order to build a healthy welfare society by developing better-quality medicines.

ProductsOur sales turnover was around 70 million dollars in 2011 and we have been exporting around 15 countries mainly south east asia, south america and africa. We have been doing business with Vietnam for more than 15 years and established representative office in 2006. For creating new markets, we put more effort on CTD documentation as well as finding potential business partner. As a result, we are about to export bug bite patch to America in this year and 2 products are in the process of registration in China.

Followings are our main products.- Aceren capsule(Diacerhein): Rheumatoid arthritis, osteoarthritis - Resnalin patch(Tulobuterol): Bronchial asthma and sepsis- Kebanon plaster/cataplasma(Ketoprofen): Traumatic inflammation of muscles, strains and sprains- Flospan tablet/solution(Phloroglucinol): Renal and urinary colic hepatic, gall bladder and spasmodic colic, intestinal colic and dysentery syndrome- Cephamethyl tablet capsule(Methylol cephalexin lysinate): Bronchiectasis, bacterial pneumonia, otitis media, mastoiditis, paranasal sinusitis, tonsillitis, pharyngitis etc.- Protase tablet(Bromelain, Crystallized Trypsin): Fracture, sprain, internal, external and incarcerated hemorrhoid after proctoptosis, hemorrhoidal surgery, hematoma and thrombosis- Warfarin tablet(Warfarin sodium): Phlebothrombosis, embolism, pulmonic embolism and coronary artery occlusion

R&D PipelineWe have 3 factories and 3 laboratories. 1st factory is for producing tablet, ointment etc. and 2nd factory is for transdermal products. 3rd factory is mainly for law material synthesis study and manufacturing. Currently following products are under development; Voglibose(glucose-lowering), Sildenafil ODF(erectile dysfunction), Tadalafil raw material(erectile dysfunction), Rivastigmine (Anti-dementia drugs) Nicotinate (Anti-smoking aids) etc.We are also proud of our anticancer drug DHP107, which developed the paclitaxel, a medicine used formerly only for injections that now can be used orally, and this is the world’s only single agent oral paclitaxel at does not have an absorption enhancer. Moreover we are continuing our research on transdermal products using the drug delivery system (DDS) technology.

· Company Dae Hwa Pharmaceutical Co. Ltd.· CEO Han Koo, Lee· Specialty Medical products· Location Seoul· Homepage www.dhpharm.co.kr

Aceren capsule

Resnalin patch

Kebanon plaster

Flospan tablet

Cephamethyl tablet/capsule

Respecting life & Serving Society

Dae Hwa Pharmaceutical

Pharmaceutical

Pharmaceutical

1918

CONTACT US

SinHo Choi• Phone : +82-2-2204-6975• E-mail : [email protected]

Andy Lee• Phone : +82-2-2204-6971• E-mail : [email protected]

Be a partner who protects healthy life of human beings based on reliability and trust of customers.Since the establishment in 1958 with a founding idea of "Realization of human health", Daewon Pharm. Co., Ltd. has made the best efforts for human health and happiness through manufacturing and providing specialized medicines. We produce reliable and safe medicines by securing world-class manufacturing facilities and superior R&D capabilities.

Hyangnam GMP Plant

The Hyangnam factory of Daewon Pharm. Co., Ltd. is equipped with superior manufacturing facilities and quality management system and has produced over 150 of medicines, such as solid dosage medicines, liquid dosage medicines, injectable medicines, sex hormone medicines and so on. The Hyangnam factory of Daewon Pharm. Co., Ltd. secures competitiveness to manufacture world-class products with cutting-edge facilities, in conformance to the cGMP (Current Good Manufacturing Practice) criteria.

Research and DevelopmentThe Central research institute of Daewon Pharm. Co., Ltd. has been developing ETC products in various areas and, finally, in 2007 our research endeavor achieved the dream of developing a new chemical entity which upgraded our institute's position to the global level. Gwanggyo R&D Center and Gunja R&D Center as the center figure, Daewon Pharm. Co., Ltd. has sought to strengthen research and development capability and the product pipeline.

ExportWith its first export to Vietnam in 1994, Daewon Pharm has made eye-opening achievements of exports. Now, we export our products to 35 countries such as China, Latin America, Middle East, CIS, and Africa. Daewon is exporting about 50 products and is expanding its export volume with products such as Pelubi tablet, a new chemical entity, and Oramin Capsule, multi-vitamin supplement with Korean Ginseng.

products

Oramin Capsule

World’s favorite multivitamin, Oramin Cap., by Daewon contains high quality Korean ginseng and royal jelly as well as all sorts of vitamin and minerals necessary for vital daily life. Oramin, our representative global brand, demonstrates the superiority of Korean ginseng all over the world, being ranked first out of multivitamin brands in 4 countries.

Pelubi tablet(the 12th new medicine in Korea)

The Pelubi tablet, a series of NSAIDs, was developed in the whole process from raw materials to end product only by Daewon Pharm. Co., Ltd., and certificated as the 12th new medicine by Korean Food and Drug Administration. It is a highly effective NSAIDs for pain relief which has less side effects than existing NSAIDs products.

· Company Daewon Pharmaceutical Co., Ltd.· CEO Baek, Seung Ho / Baek, Seung Ryel· Specialty Drug manufacture and sales· Location 229-3 Yongdap Dong, Sungdong-Gu, Seoul, Korea· Homepage www.daewonpharm.com

Oramin Capsule

Pelubi tablet

Reliable partner for Human Health

Daewon Pharm

Pharmaceutical

Pharmaceutical

2120

CONTACT US

Global Business Development and License Out• Mr. Seong ho Jeon, General Manager, Global Strategy Dept.• Phone : Tel: Phone : +82-2-550-8372• E-Mail : [email protected]

Early Stage Collaboration and License In/Out• Mr. Kangsik Yun, General manager, R&D Strategic planning Team • Phone : +82 31-270-8320• E-Mail : [email protected]

Daewoong Pharmaceutical is the No. 1 seller of prescription drugs in the Korean market.

Established in 1945, Daewoong Pharmaceutical Co., Ltd. is the largest seller of prescription drugs in Korea. Daewoong operates the best manufacturing facilities and has professional expertise in marketing and sales promotion, as well as capacity for R&D and an efficient management system. In collaboration with multi-national pharmaceuticals, it makes every effort to launch the-state-of-the-art pharmaceutical products and medical devices to the global market. Presently in 2012, Daewoong has the largest number of blockbuster products among Korean pharmaceutical companies. This fact casts Daewoong in a pivotal role for the Korean pharmaceutical market and extends its marketing scope to the overall Asian market including China and Southeast Asia. In addition, Daewoong is also currently working to enter the EU and USA markets.

The reinforcement of R&D capacities through the establishment of R&D centers in China, India and the USA.

Daewoong Pharmaceutical Co., Ltd. has strengthened its R&D capacities on a global scale through the establishment of R&D centers in China, India and the USA in addition to its Korean center for R&D. The Daewoong R&D center in Korea is working to develop biological new drugs and incrementally modified new drugs, as well as new chemical entities (NCE). The India Research center in Hyderabad, India is managing the release of global products, developing new pharmaceutical technology and conducting global clinical trials. In addition, the R&D center located in China focuses on the development of new pharmaceutical technology and the introduction of natural new drugs. The US corporate location in Rockville, Maryland plays a strategic role in the establishment of Daewoong Pharmaceutical Co., Ltd. as a global pharmaceutical manufacturer and a hub for the distribution of Daewoong products.

R&D PipelineNew Chemical Entities

Code MOA Description Development StatusR Pre Ph I Ph II Ph III M

DWP05195 TRPV1 Antagonist Neuropathic Pain lDWP10019 DNA Pol Inhibitor Hepatitis B Virus Infection lDWP09031 Aggregation Inhibitor Alzheimer Program lDWJ205 Fungicidal Antifungal-Fungicidal Program lDWJ206 APA(Reversible) Antiulcer Program lDWJ208 Ion Channel Blocker Cancer Pain, Low-Back Pain l

Biologics


DWP418 TERT-Specific Oncolysis Gene Therapy-Oncolytic Adenovirus lDWP422 TNF Blocker Anti-Rheumatioid Arthritis Fusion Protein lDWP438 Therapeutic Antibody Anticancer Monoclonal Antibody lDWP431 BMP-2 Osteogenic Bone Morphogenetic Protein l

Incrementally Modified Drugs


IMD-01 GI Motility Enhancer Sustained Release lIMD-02 Hyperlipidemia/Hypertension Combination Drug lIMD-03 Alzheimer’s Disease Patch lIMD-04 Erectile Dysfuction Chewable Tablet l

· Company Daewoong Pharmaceutical Co., Ltd.· CEO Lee, Jong Wook· Specialty Small-molecule new drugs, biological new drugs, natural new drugs· Head Office 163-3, Samsung-dong, Kangnam-gu, Seoul, Korea· Homepage www.daewoong.com

Pharmaceutical Company with the No.1 Sales of Prescription Drugs in Korea

Daewoong Pharmaceutical

Pharmaceutical

Pharmaceutical

2120

Jin Soo Lee, Director• Phone : +82-31-270-0601• Email : [email protected]

CONTACT US

Moon Jeong Leem, Director• Phone : +82-2-2021-9580• Email : [email protected]

Dong Wha Pharm, as Korea’s first and oldest pharmaceutical company, is pursuing the ultimate goal of pharmaceutical industry, which is the development of new drugs.

Whal Myung Su, Korea’s first western-style medicine, by integrating the advantages of Western medicine into the royal court’s secret recipe in 1897, the first year of The Great Korean Empire. Furthermore, many pharmaceutical products such as Fucidin ointment, Lacteol and Pancold A etc., have been developed after Dong-Wha Pharmaceutical Research Institute was founded in 1973. Since present state-of-the-art laboratory building was built in 2010, it is now set to become a global hub for new drug development. The Chungju Industrial Complex (established in 2009) is equipped with equipment and facilities that satisfy Current Good Manufacturing Practice (cGMP) Regulations of US F. D. A. In addition, the plant has been evaluated as a world-class pharmaceutical company by the installment of high-tech plant automation system. Utilizing multi-component resources, Dong Wha strategizes to develop numerous superior medicines, the most advanced drugs and new pharmaceutical products.

ProductsA new quinolone antibiotic(PhaseIII completed)

New fluoroquinolone antimicrobial agent(Zabofloxacin, DW224) has broad antibacterial activities. It has also excellent activities against RTI pathogen. Through preclinical and clinical studies, it shows good safety profile and the following advantages.1) More active than any other Quinolones (in vitro, in vivo)2) Highly active against respiratory tract infection pathogen (Gram(+); S.pneumoniae, S.aureus, S.pyogenes and M.catarrhalis)3) Good safety profile (in mouse, rat and dog)4) No phototoxicity

R&D PipelineProject Status Characteristic & Merit Remark

Zabofloxacin(DW224)Quinolones Antibiotics

PhaseIIcompleted

• Gram (+) resistant bacteria, respiratory tract infections, particularly pneumoniae

Licensing out to PBB(USA)

DW1029Diabetic nephropathy Phase II

• New herbal drug• Excellent effect on diabetic nephropathy• Safety & low side effect

DW1350Osteoporosis

Phase Icompleted

• Perform a dual action mechanism - inhibition of bone resorption - promotion of bone formation • Superior safety

Licensing out to Teijin(Japan)

DW1006Schizophrenia Preclinical • Dopamine receptor antagonist

· Company DONG WHA PHARM· CEO Je Hwa Park· Specialty 1) Antibiotic 2) Kidney disease 3) Osteoporosis 4) Schizophrenia · Head Office 5 Soonwha-dong, Joong-gu, Seoul, Korea · Homepage www.dong-wha.co.kr

Oldest to Best

DONG WHA PHARM

Pharmaceutical

Pharmaceutical

2322

The No.1 pharmaceutical company in Korea

Dong-A Pharmaceutical Co., Ltd. is the No.1 pharmaceutical company in Korea, with annual pharmaceutical sales of USD 769.8 million (KRW 846.8 billion) in 2010.

From STILLEN to ZYDENA

As for R&D, Dong-A was the first of its kind in South Korea to establish a research laboratory. Extensive, concentrated investments have been made in R&D to discover and develop innovative medicines, resulting in the launch of various products from STILLEN (Artemisia Extract, Gastritis) in 2002 to ZYDENA (The 4th PDE-5 inhibitor in the world, Erectile Dysfunction) in 2005.

Innovative new drugs, biopharmaceuticals and new formulation products

Currently, a wide range of research projects are in development, including innovative new drugs, biopharmaceuticals and new formulation products. For the global development of the research projects, Dong-A is also pursuing licensing-out opportunities and seeking potential partnerships that can share mutual benefits through the development of Dong-A’s pipeline in the overseas market.

R&D History PipelineCode Name (Brand Name) Indication Description Latest Phase Licensing AvailabilityNew Chemical Entity DA-8159 (Zydena ®) Erectile Dysfunction PDE-5 Inhibitor Launched (Korea) / Ph III (USA) Some Territory AvailableDA-8159 Portal Hypertension PDE-5 Inhibitor Ph II (Europe) Some Territory AvailableDA-8159 BPH PDE-5 Inhibitor Ph II (USA) Some Territory AvailableDA-8159 PAH PDE-5 Inhibitor Ph II Some Territory Available

DA-7218 Infection(ABSSSI) OxazolidinoneClass Antibiotic Ph III (USA)

DA-6034 Gastritis, Dry Eye Flavone Derivative Ph III / Ph II AvailableDA-1229 Type 2 Diabetes DPP-4 Inhibitor Ph II AvailableDA-8031 Premature Ejaculation SERT Inhibitor Ph I Available

PhytomedicineDA-9701 Functional Dyspepsia Herbal Extract Launched(Korea) AvailableDA-9801 Diabetic Neuropathy Herbal Extract Ph II Available

Pharmaceutical Products

DA-3801 (Gonadopin ®) Infertility Recombinant FSH Launched (COH in ART)Ph III (Ovulation Induction) Some Territory Available

DA-3030 Diabetic Neuropathy G-CSF Ph II AvailableDA-3031 Neutropenia PEGylated-G-CSF Ph III AvailableDA-3051 Multiple Sclerosis Interferon-β Ph III (Brazil) AvailableDA-3091 Type 2 Diabetes Long-acting Exenatide Ph I AvailableDA-3607 Brain Tumor TRAIL Ph I AvailableA-3803 Infertility Recombinant hCG Ph III Available

CONTACT US

Eun-Ju Jang Deputy General Manager, Business Development & Out-Licensing Team.• Phone : +82-2-920-8212• E-Mail : [email protected]

· Company Dong-A Pharmaceutical· CEO Won-Bae Kim· Specialty ETC· Location 252 Yongdu-dong, Dongdaemun-gu, Seoul, Korea · Homepage www.donga.co.kr

A respected world-class companythrough innovative pharmaceutical products

Dong-A Pharm

Pharmaceutical

Pharmaceutical

2322

CONTACT US

• Phone : +82-2-2191-9859• Fax : +82-6234-0589• E-Mail : [email protected]

Dong Kook Pharmaceutical is marching into the world with global competitiveness.

For the past 40 years, Dong Kook Pharmaceutical has made continuous efforts to uphold respect for life and healthy national lives on the basis of corporate philosophy of creativity, harmony and credibility.From the early stage since its foundation, Dong Kook Pharmaceutical has concentrated on R&D and technology innovation through which new products were developed one after the other. Since the company was listed on the KOSDAQ in May 2007, Dong Kook Pharmaceutical’s strong R&D capabilities and corporate values have been recognized widely. Today, Dong Kook Pharmaceutical is being reborn as a global enterprise that has proven its potential power to the whole world.

Dong Kook Pharmaceutical is well known for its OTC products boasting of high brand values, e.g. Insadol, a domestically top-selling medicine for gingival disease, Madecassol, an herbal-compound wound care medicine, Oramedy, a stomatitis medicine, and Feramin Q, a medicine for menopausal symptom ; whose efficacy and safety have been proven through the clinical studies in domestic and foreign countries. Besides OTC products, Dong Kook Pharmaceutical has also been well recognized in and outside Korea with the superiority of the products and the competitive product portfolio in the field of prescription medicines.Dong Kook Pharmaceutical has developed and produced outstanding therapeutic products through various clinical trials, e.g. Pamiray, the contrast medium produced using independently synthesized API as the first attempt in Korea, and Lorelin Depot, an anti-cancer agent, earning raves in both domestic and overseas markets.

In 2006, Plant 2 acquired a rating of Grade A, the highest grade, in the injection sector from the GMP (Good Manufacturing Practice) assessment rating system. Plant 3 followed suit in 2008, receiving a Grade A rating during the assessment rating conducted by the government; thus proving high-level GMP management. For the first time in Korea, Dong Kook Pharmaceutical met the European GMP standard in the injection sector; even in the API sector, Dong Kook Pharmaceutical owns products complying with the EU Guidelines of EDQM (European Directorate for the Quality of Medicines).

Currently, Dong Kook Pharmaceutical exports finished pharmaceutical products and API to over 50 countries around the world. Specially, Dong Kook Pharmaceutical continuously expands its global networks centered on EU, Japan, and other advanced countries with the strict regulations for pharmaceuticals. It seeks to grow into a global leading pharmaceutical company that is trusted and loved by all domestic and overseas customers backed by the greatest global competitiveness.

No. The name of Product Main Ingredient Use(Indications)1 LIPOSSOL OINTMENT Centella asiatica Skin damage, traumatic wounds

2 PAMIRAY INJECTION Iopamidol X-ray contrast media for neuroradiology

3 PERIDOL TABLET Extract of the unsaponifiable fraction of Zea mays Parodontopath, gingivitis

4 POFOL INJECTION Propofol 10mg per 1ml Induction and maintenance of general anaesthesia

5 TEICOPLANIN INJECTION Teicoplanin Skin and soft tissue infections6 DURAKINASE INJECTION Streptokinase Acute myocardial infarction7 LORELIN DEPOT INJECTION Leuprorelin acetate Prostatic Cancer

R&D Pipeline

· Company Dong kook Pharm. Co., Ltd.· CEO Lee, Young Wook; Oh, Hung joo· Specialty Pharmaceutical· Location 997-8, Daechi-2dong, Gangnam-gu, Seoul, Korea· Homepage http://www.dkpharm.co.kr/english

Human & Life

Dongkook Pharm

Pharmaceutical

Pharmaceutical

2524

CONTACT US

Sung-Ick ParkGeneral manager Business Development Division• Phone : +82-31-260-9358 • Fax : +82-31-260-9408• E-Mail : [email protected]

Hong-kwon Woo, Manager,Global Business TeamOverseas Business• Phone : +82-31-260-9415 • Fax : +82-31-260-9491• E-Mail : [email protected]

Green Cross is an exemplary R&D-oriented company that leads the biotech-nology industry in Korea. This is clear given what Green Cross has achieved since its foundation in 1967. GCC has pioneered in the field of biopharmaceuticals, such as vaccines, plasma-derivatives, diagnostics, recombinant proteins and therapeutic antibodies. GCC has been well known for the R&D and commercialization of ‘Hepavax B’, a world’s biggest selling hepatitis B vaccine, ‘Hantavax’, a world’s first epidemic hemorrhagic fever vaccine, and ‘Suduvax’, a world’s second chicken pox vaccine. A complete flu pipeline includes seasonal flu vaccine (GCFLU®), H1N1 vaccine, avian flu vaccine and etc. GCC is also pursuing opportunities in rare diseases developing therapies for Hunter syndrome (HunteraseTM) and Fabry’s disease (GC1119). With continuous investment in R&D, its portfolio now includes gene/cell therapeutics and small molecule drugs. In 2011, GCC earned $616 million in revenue recording it as Korea’s 3rd largest pharmaceutical company and invested $51.7 million in R&D which is one of the highest in Korea.

ProductsPlasma Fractions & RecombinantsStarting from the nation’s first Albumin production in 1971, Green Cross currently manufactures more than 12 plasma fractions including immunoglobulin, anti-hemophilic factors, and anti-thrombin factor. Recent innovations include ‘BDD rhFVIII (GreenGeneTM F)’, a 3rd Generation of recombinant Factor VIII for hemophilia A treatment.

VaccinesWe succeeded to develop the world’s third Hepatitis B vaccine in 1983, the world’s first epidemic hemorrhagic fever vaccine in 1988. With the construction of Hwasun plant, a vaccine-oriented manufacturing facility, the influenza vaccine GC Flu(GC FLU) became the fourth in the world to obtain PQ (Pre-Qualification) approval from the WHO. Green Cross is able to prepare pandemic vaccine such as the H1N1 new influenza vaccine.

ETC& OTC MedicinesGreen Cross has provided a broad range of ethical medicines in the field of cardiovascular disease, cerebrovascular disease, metabolic disease including diabetes, hypertensive disease. Along with poultices (one of our core OTC products), we also have provided OTC products in respiratory, dermatology and immunology.

R&D Pipeline

· Company Green Cross Corp.· CEO Il-Sup, Huh· Specialty Plasma Derivatives & Recombinant Proteins, Vaccines, ETC& OTC Products· Location 303 Bojeong-dong, Giheung-gu, Yongin, Korea · Homepage www.greencross.com

Project Indication R NC IND Ph I Ph II Ph III NDA A MGCFLU™ Seasonal fluGC1109 AnthraxGC1107 Tetanus, diphteria

GC3104A D.T.P prophylaxisGC3106A Seasonal flu(Cell culture)MG1111 Varicella

GreenGeneTM F Hemophilia A

HunteraseTM Hunter syndrome

IVIG-SN Infections

GCPGC NeutropeniaGC1113 AnemiaGC1119 Fabry’s diseaseGC2107 Anti-thrombotics

Shinbaro cap.™ OsteoarthritisGC3101A GERDMG4101 Cancer

Vaccine

Protein

Natural product

Cell therapy

US

US

US

Development of medications that are difficult to produce but necessary

Green cross

Pharmaceutical

Pharmaceutical

2524

CONTACT US

Soonim Lee, Director• Phone : +82-2-2204-1753• E-mail : [email protected]

HanAll BioPharma is an R&D-oriented pharmaceutical company, cur-rently listed on the Korean Stock Exchange (KOSPI).

It has been developing innovative and unique small molecules and large molecules to treat major diseases for the global market. The company has proprietary programs with broad therapeutic applications including oncology, immunology, endocrinology, infectious diseases, ophthalmology, and cardiology.

R&D PipelineProduct Information

HL156CAN

HL156CAN is a new chemical entity which activates AMP-activated kinase (AMPK) and inhibits Epithelial-to-Mesenchymal Transition (EMT). The activated AMPK inhibits mTOR thereby produce anti-proliferation effect and prevents protein synthesis which leads to autophagy and apoptosis in cancer cells. Moreover, HL156CAN selectively target cancer stem cells and inhibit proliferation as well as prevention of the EMT which ultimately results in anti-metastatic effect. HL156CAN is currently at pre-clinical stage.

HL143(Hanferon™)

HL143, a single amino acid variant of native IFN-alpha-2a which is a biobetter product. By utilizing Resistein™ technology, Hanferon™ is protease resistant therefore has longer half-life and improved AUC compared to the native IFN-alpha. Recently, HanAll has completed phase II trial in HCV patients comparing its efficacy and safety against Pegasys(R) within US.

HL032(Vitatropin™)

HL032 (Vitatropin™), a orally available human growth hormone which would be the first. By using Resistein™ technology, HL032 possess greater protease resistant characteristic with significantly higher bioavailability compared to the native human growth hormone after oral administration. HanAll has completed phase I trial in Korea comparing its PK profile against Genotropin(R).

HL161(Novel Target mAb)

A fully human monoclonal antibody targeting the Fc Neonatal Receptor (FcRn) for the treatment of autoimmune diseases caused by IgG autoantibodies. FcRn plays an essential role in IgG homeostasis by regulating a salvage pathway that prevents lysosomal degradation of IgG, thus contributing to a long half-life in the circulation. While FcRn-mediated half-life extension is beneficial for IgG antibody responses against pathogens, it also prolongs the serum half-life of IgG autoantibodies and thus promotes tissue damage in autoimmune diseases. By blocking FcRn, HL161 can effectively reduce overall IgG concentration similar to IVIG and plasmapheresis. HL161 is currently at pre-clinical stage.

HL009

HL009 is an adenosylcobalamin liposomal gel, with three different potential mechanisms of actions for the treatment of atopic dermatitis. HL009 can bind to nitric oxide (NO) which causes dermatitis; also it can inhibit inducible nitric oxide synthase (iNOS) to further reduce NO levels. From an immunology perspective, HL009 can activate T regulatory cells which excrete IL-10 and TGF-beta suppressing immune response. HanAll has completed phase II trial in Korea and currently conducting phase II trial in US.

· Company HanAll BioPharma Co. Ltd.· CEO Dr. Sungwuk Kim· Specialty 1) Oncology & Fibrotic Disease 3) Infectious Disease 4) Immunology 5) Endocrinology· Location 11-10 Sincheon-dong, Songpa-gu, Seoul, Korea· Homepage www.hanallbiopharma.com

Innovative Medicines to Improve the Quality of Human Life

HanAll BioPharma

US BRANCH

S. T. Oh, Director• Phone : +1-301-738-3980• E-mail : [email protected]. Inc.9605 Medical Center Drive, Suite #290Rockville, MD, 20850

Pharmaceutical

Pharmaceutical

2726

HANDOK, founded in 1954, has been dedicated to developing and providing innovative pharmaceutical products including prescription drugs and OTC drugs, initially through technology collaboration with Hoechst of Germany in 1957, and later by establishing joint venture with Hoechst of Germany in 1964. Since the company’s initial public offering in 1976, HANDOK, as a joint venture, has acquired advanced technologies from prominent multinational pharmaceutical companies, and had contributed to bring foreign capitals into Korea. HANDOK is one of the most successful and oldest joint venture in Korea, and has striven to become one of the most outstanding pharmaceutical companies in 21st century through the solid partnership with Sanofi-Aventis. It is HANDOK’s values and mission to become a company that makes the highest quality pharmaceutical product that people can trust and where the talented people wish to work on their dream with passion. HANDOK strives to innovate in management by hiring the talented people who fit the company slogan ‘The Health Innovator’, and placing them in right places. HANDOK is also committed to the highest standards of ethics and integrity and to the transparency in management.

HANDOK gives priority to the integrity over the size of the company and will continuously strive to become a respected, leading pharmaceutical company not just in Korea but also in the world that improves the people’s health and contributes to the development of country.

Main ProductsAmaryl M(Glimepiride + Metformin HCl)

- is the first fixed dose combination of glimepiride and metformin HCl in Korea.- is the combination with Sufonylurea + Metformin recommended by global guideline. - provides glycemic control with favorable safety pofile.- significantly reduces HbA1c compared to metformin.- is superior to Metformin in FPG reduction.- allowed more patients to achieve glycemic target than Metformin.- has been registered by 57 centuries.

Amaryl Mex(Glimepiride + Metformin HCl)

- is the first patented sustained-release fixed dose combination of glimepiride and metformin HCl (Winner of Korea New Drug Award, 2009)- was applied by DRM technology(Dual Release Micro-coating technology) Three-layer structure of Amayl-Mex- one a day can improve patients’ compliance.- has been registered by 13 centuries.

CONTACT US

SoHyun KwonHead of Licensing & Business Development• E-mail : [email protected]

· Company HANDOK Pharmaceuticals Co., LTD· CEO Kim YoungJin · Specialty Pharmaceutical product(ETC, OTC), Medical devices· Location 132, Teheran street, Gangnamgu, SEOUL, 135-923· Homepage www.handok.co.kr

Amaryl M

Amaryl Mex

The Health Innovator

HANDOK Pharmaceuticals

Pharmaceutical

Pharmaceutical

2726

CONTACT US

SUNG DAE, KIM (Manager / Overseas trade)• Phone : +82-2-3489-6127• E-Mail : [email protected]

With the corporate mission of protecting the precious human life from various forms of diseases, HANLIM has consistently endeavored to improve the health standards of people, and we have grown to become one of the leading companies in Korea.In 1993, the future-oriented GMP factory was completed together with the founding of the central research center. As a part of the long-term investment scheme of the company, we continue to make a great investment in accumulating advanced technologies and reorganizing manufacturing facilities lately to enhance the health of mankind as a leading pharmaceutical company.

Products[1] DAGES CAP : Digestives (Pepsin 25mg, Papain 50mg, Diastase 15mg, Cellulase 15mg, Pancreatin 50mg, Pancrelipase 13mg, UDCA 25mg) - Gastric, enteric and pancreatic secretive insufficiencies- Anorexia, meteorism, flatulence, steatorrhea, fermentative, dyspepsia with intestinal irregularity- Dyspepsia in cholecystectomized patient- Superalimentation during convalescence and fattening diets- Biliary secretive insufficiency- Cholelithiasis, cholecystitis, cholangitis, jaundice

[2] LODIEN TAB : Antihypertensives (s-Amlodipine Nicotinate 2.5mg/5mg tab.)- Hypertension- Myocardiac ischemia due to stable obstruction of coronary artery (stable angina) or vasospasm and vasoconstriction of coronary artery system (unstable angina)

[3] HYALURON EYE DROP : Epithelial protector of cornea & conjunctiva (Hyaluronate Na.1mg/mL)- Endogenic disease such as Sjogren’s syndrome, Stevens-John’s syndrome, dry eye syndrome and so on- Exogenous disease due to Surgical procedures, Medicine, Trauma, Wearing of hard contact lens

[4] NASATIVE NASAL SPRAY (Mometasone furoate 0.5mg/mL)- The treatment of nasal polyps - The treatment of acute rhinosinusitis without severe bacterial infection

R&D PipelineCategory Project Indication Development stage

Incrementally

modified drugs

HL-CER osteoarthritis phase IHL-SAS antihypertensive phase ILodivixx antihypertensive phase IEntelon osteoarthritis phase III

New drugsHL-217 AMD preclinicalPM-014 COPD, asthma preclinical

· Company HANLIM PHARM. CO., LTD.· CEO JAE YOON, KIM· Specialty R&D and manufacturing of API/BPIs, pharmaceutical product· Location 1656-10, Seocho-Dong, Seocho-Gu, Seoul, Korea· Homepage http://www.hanlim.com

DAGES

LODIEN

HYALURON

NASATIVE

Thinking of the human health and the future

HANLIM PHARM

Pharmaceutical

Pharmaceutical

2928

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company in Korea with the highest R&D investment for several years.Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD &FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies.As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

R&D PipelineOncology Pipeline (as of Aug. 2012)

Pipelines Characteristics Development StageOraxol Paclitaxel +HM30181A Phase II Licensed out to Kinex (US)

Oratecan Irinotecan + HM30181A Phase I Licensed out to Kinex (US)HM781-36B Orally active pan-Her inhibitor Phase I

KX-01 Src tyrosine kinase and tubulin polymerization inhibitor Phase II HM61713 EGFR mutant selective inhibitor Phase I

LAPSCOVERY(Long-acting Protein/Peptide Discovery Technology) Pipeline (as of Aug. 2012)

Candidates Characteristics Development StageLAPS-Exendin (HM11260C) Long-acting Exendin-4 analog Phase II (EU/US)

LAPS-hGH (HM10560A) Long-acting hGH Phase II (KR/EU)LAPS-GCSF (HM10460A) Long-acting G-CSF analog Phase I (KR/US)LAPS-EPO (HM10760A) Long-acting EPO Phase I (KR/US)

LAPS-IFNα (HM10660A) Long-acting IFNα Phase I (EU)LAPS-Insulin (HM12460A) Long-acting Insulin Preclinical

Fixed-dose Combination Pipeline (as of Aug.2012)

Candidates Characteristics Development StageAmosartan® Amlodipine / Losartan Clinical study in ex-Korean territories

HCP0703 Pseudoephedrine / Levocetirizine Phase IIIHCP0912 Irbesartan / Atorvastatin Phase IIIHCP1102 Montelukast / Levocetirizine Phase II, Phase III

HCP0613 Mosapride / Bacillus subtilis / Streptococcas feacium Phase II

HCP1103 Ambroxol / Levodropropizine Phase I HCP1104 Aceclofenac / Eperisone Phase I HCP0910 Fluticason propionate / Salmeterol Phase I

· Company Hanmi Pharmaceutical. Co., Ltd.· CEO Gwan-Sun Lee· Specialty R&D based pharmaceutical products· Location 14, Wiryeseong-daero, Songpa-gu, Seoul, 138-724, Korea· Homepage www.hanmipharm.com

CONTACT US

Licensing OutChristine LeeAssistant Manager of Global Business Development• Phone : +82-2-410-8761• E-mail : [email protected]

Licensing InSi-Young JungSenior Manager of In-Licensing• Phone : +82-2-410-9292• E-mail : [email protected]

Export (Finished Products/APIs/CMO Business)Sangjae LeeSenior Manager of Export Business• Phone : +82-2-410-9078• E-mail : [email protected]

Information ManagementKyoung Woo Lee Licensing Information Manager • Phone : +82-2-410-9291 • E-mail : [email protected]

R&D driven pioneer For innovation in life sciences

Hanmi Pharmaceuticals

Esomezol Cap.

Amosartan Tab

Pharmaceutical

Pharmaceutical

2928

CONTACT US

Edward Kim Business Development Team Manage• Phone : +82-2-2600-3848 • E-Mail : [email protected]

With the long history since 1965, Hyundai Pharmaceutical Group (here after HDP) has been growing up for the best R&D pharmaceutical company in Korea and now heading to the world beyond Asia.HDP is committed to creating the best value for mankind through its innovative product development, human-istic management and social responsibilities.Through relentless pursuit of innovative effort, we have been given for several renown awards such as Best Enterprise by Korean Management Association in 1984, the Best Productivity Company among all listed com-panies in Korea in 1997, the President Award in National Safe and Quality Management in 2005 and 2009 and lately selected as the Advanced technology center (ATC) and innovative pharmaceutical company in 2012 by Korean government.With these recognitions, as well as our strengths in manufacturing, qualified human resources and capabilities to develop innovative pharmaceutical products, HDP has demonstrated and is now fully ready to go beyond Asian border ourselves and with our esteemed Global partners.

ProductsTherapeutic Class Product name Composition Indication company

Cardiovasculardisease

SYSCOR ER nisoldipine Hypertension BayerZESTRIL TAB anhydrous lisinopril Coronary Heart Disease

AstrazenecaTENORETIC TAB atenolol, chlorthalidone HypertensionTENORMIN TAB atenolol HypertensionTAREG Valsartan Hypertension

NovartisCO-TAREG Valsartan and HCTZ Hypertension

RespiratoryLEVOTUSS SYR/ TAB levodropropizine Acute and Chronic Bronchitis DompeSURFOLASE CAP acebrophylline Acute and Chronic Bronchitis PoliALEGYSAL DRY TAB pemirolast potassium Allergy MTPG

Central Nervoussystem

ACTIC ORAL TAB fentanyl citrate Breakthrough cancer pain TevaTAMIRINE TAB galantamine hydrobromide Anti-Dementia

HDPPAXETIL TAB/ CR TAB paroxetine HCl AntidepressantMIRAP TAB pramipexole dihydrocholoride Anti-Parkinson

Women’s health

NORLEVO 1 TAB levonorgestrel Emergency ContraceptiveHRAELLAONE TAB ulipristal acetate Emergency Contraceptive

GYNOFLOR VAG TAB estriol, lactobacillus Vaginal Infection

HemostaticsTACHOCOMB collagen, fibrinogen, thrombin,

aprotinin Hemorrhage during surgeryTakeda

TACHOSIL fibrinogen, thrombin Hemorrhage during surgery

Ophthalmologicals OCUVITE PRESERVISION TAB

ascorbic acid, beta-carotene, cupric oxide, Vit E, zinc oxide Supplement (OTC) Bausch

&Lomb

R&D PipelineCriteria Products Indication Type DS PC Ph I Ph II Ph III NDA

NCE

HOB 046 Type 2 Diabetes GPR119HOB 047 Type 2 Diabetes 11 beta HSDIHOB 050 GI BioticHOB 003 Chronic Renal Insufficiency Anti-oxidant

IMD

HOB 064 Obesity Natural compoundHOB 049 Osteoporosis Osteoclast InhibitorHOB 048 Cough Suppressant Peripheral antitussiveHOB 051 Bronchitis Muco-activeBPS 005 CNS Natural compound

HOB 058 AlopeciaVasodilator and Androgen

receptor antagonistand Androgen receptor

SURFOLASE CR Bronchitis, Asthma Phosphodiesterase inhibitorLEVOTUSS CR Bronchitis Non-opioid antitussive

The Company which has dream of healthy society

Hyundai Pharmaceutical

Pharmaceutical

Pharmaceutical

3130

ILDONG Pharmaceutical was founded in 1941 based on the ambition to be the protector of the health of people. The finished product manufacturing plant and pharmaceutical raw material plant strive to achieve zero defect manufacturing through advanced production facilities, strict compliance with GMP regulation and extensive quality control.We export finished drug and APIs to over 20 countries, and are actively involved in new drug development and joint ventures overseas.

ProductsWe are ranked among the top in the domestic OTC market backed by our power brands Biovita which is Korea’s first lactobacillus probiotic product and Aronamin which occupies indisputable No.1 position in the Korean multi-vitamin complex market. These two powerful OTC products have been exported to around world.

We are also reliable provider of ETC drug to domestic and overseas market. Especially, we have dedicated anti-cancer plant and cephalosporin plant approved by KFDA and these plants are expected to be approved by Japanese PMDA early 2013.

We provide outstanding quality synthetic and probiotic raw material manufactured in our BGMP-certified plant to domestic and foreign pharmaceutical companies, and seek to expand the overseas market based on advanced manufacturing techniques for pharmaceutical raw materials.

R&D PipelinesILDONG Research Laboratories concentrate on new drug development, dosage form research and pharmaceutical raw material development, enriched with excellent researchers and latest research facilities.

- Intractable infection suppressants (IDP-73152) (Tasked by Ministry of Knowledge Economy)- Targeted anti-cancer drugs (Tasked by Ministry of Education, Science and Technology)- Metastasis inhibitor- General-purpose antiviral agents (Regional industrial technology development program)

- Dementia treatment- Obesity-suppressing agents- Anti-diabetic drugs (protein pharmaceuticals)- Therapeutic probiotics- Incrementally modified drugs

CONTACT US

Eric Kim• Phone : +82-2-526-3266• E-mail : [email protected]

· Company ILDONG PHARMACEUTICAL CO.,LTD.· CEO Lee, Jung-chi· Specialty Antineoplastic Agents, Probiotics, Vitamins, etc.· Location 2, Baumoe-ro, 27-gil, Seocho-gu, Seoul 137-733, Korea· Homepage www.ildong.com

Taxozen Inj

Biovita

Excellence and contribution to the Health and Happiness of Mankind

ILDONG PHARMACEUTICAL

Anti-cancer plant Cephalosporin plantLyophilized injection 10,000Vials/Cycle

Liquid injection 6,000Vials/HourTablet 240,000Tablets/Day

Capsule 320,000Capsules/Day

Lyophilized injection 60,000Vials/Cycle 30,000Vials/CycleLiquid injection 18,000Vials/Hour

Tablet 500,000Tablets/DayCapsule 300,000Capsules/Day

Dry syrup 600kg/Day

Pharmaceutical

Pharmaceutical

3130

CONTACT US

Sun Park. Ph. D.General Manager / Licensing Team• Phone : +82-2-570-3787• Fax : +82-2-570-3890 • E-Mail : [email protected]

Il-Yang will exert its efforts towards improving the national health and welfare through continuous research and efforts for the development of the most advanced medicines until all diseases in this land are health.Il-Yang Pharmaceutical Co. has tried its utmost to manufacture superior medicines for the last half a century. Since it took the first step to supply medicines in Korea, a barren land for the medical industry in 1946, Il-Yang has been advancing into a top-ranking pharmaceutical company in the world with developing on GI, Hematology, Vaccine, Virology area as well as vaccine plant established in April 2011 which has production capacity of 60 mil. doses per year. On the basis of the most advanced medical practice and pharmaceutical dispensing and a solid business footing in Korean market, Il-Yang has exported a variety of pharmaceuticals to approximately 30 countries in the world including USA and Europe, and has opened an era of overseas branch production by establishing YANGZHOU IL-YANG PHARM. CO., LTD. and TONGHUA IL-YANG HEALTH PRODUCTS CO., LTD. for manufacturing end-pharmaceuticals in China

Products1. Supect (API : Radotinib)1) 2nd generation Bcr-Abl tyrosine kinase inhibitor (TKI) for the treatment of Philadelphia chromosome positive (Ph(+)) CML.2) Indication: Ph(+) chronic myeloid leukemia (CML) in chronic phase (CP) or accelerated phase (AP).3) Development Stage : - CML-CP NDA approved in Korea by KFDA in 5th JAN, 2012. - Phase III for CML-CP has initiated in Korea, Thailand, India, and Philippines.4) Key features - No serious side effect - Early efficacy signals higher than initial MCyR response at 6 month

2. Noltec (API : Ilaprazole)

1) 14th New Drug developed in Korea2) Noltec is a Proton Pump Inhibitor that controls the secretion of gastric acid for the treatment of GU, DU, GERD/EE, NERD3) Greater effect on Severe GERD patients, low reoccurrence, no symptoms of night time heartburn, and low DDI

3. Anti-Viral agent

1) IY 5741 has been announced at American Society for Virology on 22 July, 2012 that it is 20~30 times potent than Tamiflu 2) New mechanism : it inhibits fusion function for uncoating replicase and outer layer of virus at early stage

Supect

NoltecR&D Pipeline

Compound Application (Country) Ph I Ph II Ph III NDA Marketed

Ilaprazole

GU / DU Korea, China

EE / GERDKoreaUSA

NERD Korea

RadotinibCML-CP Multi nationalCML-CP Multi national

Virology VirologyIY5741Vaccine

ongoing

ongoing

· Company IL-YANG PHARMACEUTICAL CO., LTD.· CEO DONG YEON, KIM· Specialty Urology, GI, Dermatology, Oncology, Vaccine, Biopharmaceutical· Location IL-Yang Bldg. 544-5 Dogok-dong, Gangnam-gu, Seoul, Korea· Homepage www.ilyang.co.kr

Respect humanity, Promote human’s health,Improve welfare

IL-YANG PHARMACEUTICAL

Pharmaceutical

Pharmaceutical

3332

CONTACT US

Yunseung Chung, Senior ManagerBusiness Development• Phone : +82-2-390-4921• Fax: : +82-2-390-4999• E-Mail : [email protected]

1) ISU ABXIS’ Innovative Model

“Shift from orphan drug biosimilar company to a global biotechnology company”

2) Specialized sector: Therapeutic biological drug development (Including enzyme pharmaceutical drug)

A. Experience on the full process of development from preclinical phase to Marketing phase B. Focus on the development of novel anticancer antibody drug and blockbuster biosimilar drug C. Specialized technology

- Antibody screening technology - Efficacy verification - Therapeutic antibody production - Clinical Development- GMP facility approved by 6 different countries including Korea.

3) Differentiated business model

A. Early phase licensing out of novel drug B. Expansion of biosimilar drug ⓐ Acceleration of approval for the current developing pipeline: Abcertin®, Cloninab®, ISU303 ⓑ Development for the next generation blockbuster biosimilar drug: ISU103 (Brest cancer drug), ISU202 (Rheumatoid arthritis drug) C. Business focus on the BRIC market

ProductsClotinab® (Antiplatelet antibody, Abciximab)

R&D PipelineProduct Indication Type of Product Status Launch

ClotinabⓇ Adjunct to PCI(Percutaneous Coronary Interventions) Biosimilar(ReoProⓇ) Antibody Marketed 2007

ISU302 Gaucher disease Biosimilar(CerezymeⓇ) Enzyme NDA ready Phase III 2012ISU303 Fabry disease Biosimilar(FabrazymeⓇ) Enzyme Phase II 2013ISU103 Her2 positive cancer Biosimilar(HerceptinⓇ) Antibody Preclinical Development 2016ISU202 RA and Inflammatory Diseases Biosimilar(HumiraⓇ) Antibody Preclinical Development 2018ISU201 Inflammation Novel drug Antibody IND ready -ISU104 Oncology Novel drug Antibody Lead development -ISU105 Oncology Novel drug Antibody Lead development -

Product profileA. The first biosimilar of Reopro® of Eli LillyB. GPIIb/IIIa receptor antagonists/ anti-thromboticsC. Binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and

inhibits platelet aggregationD. Indication: Adjunct to PCI (Percutaneous coronary interventions)E. Product Picture

· Company ISU ABXIS· CEO Changhoon Choi· Specialty Biological pharmaceutics development based on the technology platform for

monoclonal antibody and animal cell culture· Location Yonsei University Medical Center, 134, Seodaemungu, Seoul, Korea· Homepage www.abxis.com

Accumulation of high-value core technologies in biotechnology to develop future products

ISU ABXIS

Pharmaceutical

Pharmaceutical

3332

Contact Information

Licensing Licensing Strategy • Phone : +82_2_840_6897 • E-Mail : [email protected] Global Business Business Developtment • Phone : +82_2_840_6774 • E-Mail : [email protected] Research Project Planning • Phone : +82_2_840_6410 • E-Mail : [email protected]

JW Group provides pharmaceuticals vital for maintaining the lives of patients such as anti-cancer drugs and antibiotics, and has developed into a leading pharmaceutical company and global manufacturer of I.V. solutions. Furthermore, JW Group is exploring the new markets of OTC/healthcare and development and supply of diagnostics and medical equipment. JW Group, whose products enhance the healthy living of its customers, approaches them as a friendly corporation. JW Group is being reborn as a total healthcare group to fulfill the precious dreams and hopes of humankind.JW Group has continuously carried our research on disease based on its long-time experience and know-how in the field of pharmaceuticals, and continues to accumulate meaningful research outcomes. In addition, by establishing the Drug Discovery Center, CMC Research Center, JW Theriac and C&C Research Labs and conducting joint research projects with leading global research institutions, it has built a global R&D network for the development of new innovative drugs. JW Group’s mission to cure diseases and develop ground-breaking technologies goes on today

Major Export ProductsProduct Launch

Finished Product

1. Carbapenem Antibiotics2. Amino Acid Solutions3. General I.V. Solutions & Other Sterile Solutions4. Anticancer Agents5. Antimicrobial & Antifungal Agents6. Gastrointestinal Agents7. Topical8. Multivitamins9. Agents for Antibiotics10. Miscellaneous

API(Active Pharmaceutical Ingredient)

1. Carbapenem Antibiotics: Imipenem/Cilastatin, Meropenem2. Anti-fungals: Ketoconazole, Itraconazole, Fluconazole3. Chiral Products for Custom Synthesis & Specialty Amino Acid4. Miscellaneous

G&D Popeline

· Company JW Pharmaceutical· President Kyung Ha Lee· Specialty I.V- solutions, antibiotic, cardiovascular, gastrointestinal,

nephrology/antianaemic, anticancer and neuropsychiatryincrementally modified drug (IMD)· Location 2477 Nambusunhwan-ro, Seocho-gu, Seoul, Korea· Homepage www.jw-pharma.co.kr

LivasartanTM

FESNS® Nano oxaliplatinUR1102

JWP1101CWP232291

CreaVax RA® CWP241 CWP0403 Combiflex®

CreaVax PC® sTU199 LivasartanTM Dia-MTM

CreaVax BC® CreaVax HCC® CreaVax RCC® Actemra®

No.1 drug maker in the field of Korean ETC market

JW Pharmaceutical

Preclinical PhaseI Phase II Phase III Registration

▶ Pipeline represents progress of R&D programs since▶ Included are 12 NMEs plus 3 additional indications, 1 administration route change, and 1 advanced generic development

Small molecule NCEsBiologics

JW is focusing on developing Biologics as well as Small molecules in the areas of oncology,endocrinology and immunology by employing its novel platforms

Pharmaceutical

Pharmaceutical

3534

It has been 22 years since Kolmar Korea began to dream of beauty and health in 1990. Beginning as an Original Equipment Manufacturer(OEM), Kolmar Korea introduced and established the new business model called the ODM network, and made a ceaseless effort to develop the high-tech-field of its own pharmaceutical and functional heath food manufacturing. In addition to the technical power and quality, the leadership of Kolmar Korea is making progress in the direction toward contributing to establishment of core values, with which our business partners and end users of the products may find out the advanced beauty and heathy life.

R&DKolmar Korea reinvests more than 6% of net sales into its research and development, grafting 100 years’ worth of R&D know-how into research and development, and leading the latest trend by developing world-class pharmaceuticals, health functional foods and cosmetics. Kolmar Korea has been approved not only in domestic market but in international market for its great and predominant technology.

Global KolmarKolmar Korea has its roots in the world-wide Kolmar Group. The Kolmar Group based on Kolmar Americas Inc., which is the parent organization of Kolmar Group and was established in Milwaukee, Wisconsin, in 1921, has the world-wide network including Kolmar Japan, Korea, and China, showing off the vast scale in the world. In the global network of Kolmar equipped with 100-year-old R&D Know-how, the continuous information exchanges are carried out through the regular symposium and academic activities by affiliated research group members, so that latest data concerning marketing may be shared as well as technologies. And Kolmar Korea takes the initiative in the development history of world-wide pharmaceutical and cosmetic history.

ProductsKolmar korea has a cutting-edge technology called ‘LIDCAPS’ that enables liquids to fill into hard-shell capsules. The representative products taking advantage of the technology are Lidsen cap.(naproxen), cough-zero cap., Denti-lid cap.(Titrated extract of the unsaponifiable fraction of Zea mays L.), which have been approved by KFDA first in KOREA. Besides, Kolmar Korea’s product line-up covers virtually all the therapeutic areas such as cardiovascular system (Amlodapine tab.), dermatologicals (Mitra cap.), genito-urinary system (Taminal cap.), respiratory system (Pellium syrup.), alimentary treat (Panto-K tab.) and metabolism(Glimepirid tab.), etc.

R&D PipelineCategory Candidate Indication Development stage

New Herbal Drug

KKM0801 GI Ulcer Phase I

KKM1011 Hypertension Phase II

KKM1012 Diabetes Phase II

KKM1102 Infections Preclinical

Small MoleculesKKM0805 Osteoporosis Phase I

KKM0902 Osteoporosis Phase I

Combination ProductKKM1201 Hyperlipidemia Phase II

KKM1202 Benign Prostatic Hyperplasia Phase III

CONTACT US

Name / Position : Jin-Young Kim / Executive Director• Phone : +882-2-3485-0470• Fax : +82-2-515-1532• E-mail : [email protected]

Name / Position : Moon-Su Pyo / Director Department : Global Business Dept.• Phone : +882-2-3485-0497• Fax : +82-2-515-1532• E-mail : [email protected]

· Company Kolmar Korea Co., Ltd.· CEO Hong-Koo CHO· Specialty Pharmaceuticals/Cosmetics/Health Functional Foods· Location CNI BD 1596-3 Seocho-Dong Seocho-Gu Seoul Korea· Homepage http://www.kolmar.co.kr

Creating the value of Health and Beauty

Kolmar Korea

Pharmaceutical

Pharmaceutical

3534

Korea Otsuka Pharmaceutical is a branch of Otsuka Group International, which was established in Korea in 1982. Korea Otsuka has set as its mission to contribute to Korea’s healthcare industry, in line with which its main products include “Abilify”, an antipsychotic medication, “Mucosta”, a medicine for gastritis and gastric ulcer and “Pletaal”, an antiplatelet agent. Otsuka Pharmaceutical Group plans to make 1 trillion won to the nation by 2013 upon MOU for R&D cooperation made with the Ministry of Health and Welfare in 2009 in order to contribute to the domestic development of new medicines and the advancement of local R&D infrastructure. The total investment that Otsuka Pharmaceutical Group has made from 2009 to 2011 surpasses 50.9 billion won.

Korea Otsuka Pharmaceutical was started with the construction of the Hyangnam Plant back in September 1989. The plant acquired KGMP (Korea Good Manufacturing Practice) and BGMP (Bulk Good Manufacturing Practice) recognition in December 1990 and December 1999, respectively, and, as a result, the plant was recognized for being suitable as a material medicine manufacturing facility from the FDA in July 2000.

Korea Otsuka Pharmaceutical has a world-class level of technological power, built upon the systematization of manufacturing facilities and the advancements made in its business processes and synthesis technologies. It currently exports the materials/finished medicines produced with its competitive, technical strengths to Japan and 10 countries within South-East Asia. With other multinational pharmaceutical companies tending to look to close down their factories, Korea Otsuka Pharmaceutical is bucking this trends, with plans to expand its exports and diversify its exporting regions by establishing a firmer foothold, with a production base that covers Asia and Middle East, including its synthesis plant for Rebamipide, which was completed in October 2003. The company is currently planning to build a manufacturing line that is possible to respond to EU GMP and cGMP in order to expand the items it exports and the regions it exports to.

BusinessKorea Otsuka Pharmaceutical has production facilities based in Korea, contributing to its exports to 10 countries, including Japan, China, Philippine and Indonesia. In fact, the company has produced a medicine for global clinical trials, which requires a high-level of technology, and successfully exported this to Japan in 2011.

Korea Otsuka Pharmaceutical’s differentiated clinical development, exports and its role: 1) Korea Otsuka Pharmaceutical has amplified the advantages of clinical development environment of Korea- China-Japan, improved the efficiency of new medication development and contributed to better health care Service for Asian by developing a cure for endemic disease in relevant country

2) A development center for anti tuberculosis drug and diagnosis/medicine-taking model

3) Korea Otsuka Pharmaceutical has developed medications best suited for the country(obtained approval for Pharmaceutically modified drug, Platelet SR drug and for the world’s first approval for Abilify tablet being Efficacious for Indication of child’s diseases through clinical trials with in the country)

4) As a Korean company exporting its products to overseas, Korea Otsuka Pharmaceutical has made a great Contribution to export in the last three years(20.6 billion won in 2009, 25 billion won in 2010 and 28.4 Billion won in 2011).

CONTACT US

R&D/Export/ProductHong InpyoClinical Development Team• Phone : +82-2-3287-9200

OthersJung HyejinPlanning Team • Phone : +82-2-3287-9146

· Company Korea Otsuka Pharmaceutical Co.,Ltd.· CEO Moon, Sung-ho· Specialty The manufacture, sale, import and export of pharmaceuticals and pharmaceutical products· Location 770-9 Yeoksam-dong, Gangnam-gu, Seoul, Korea· Homepage www.otsuka.co.kr

Mucosta Tab.

Abilify Tab.

Pletaal Tab.

Otsuka-people creating new products for better health worldwide

Korea Otsuka Pharmaceutical

Pharmaceutical

Pharmaceutical

3736

Exporting 200 different drugs to 30 different countries through global marketing with infrastructure factories in USA, Vietnam, and agents in other countries. KUP ranked among Forbes’ ‘Asia’s 200 Best Under A Billion’ two years in a row

Korea United Pharm. is one and only pharmaceutical company in Korea picked by the Forbes magazine as one of the ‘Asia’s 200 Best Under A Billion’ two years in a row(2009~2010).

Designated as an Advanced Technology Center

Korea United Pharm.‘s Central Research Institute was approved as an Advanced Technology Center on July, 2004 by the Korean government. To be the Advanced Technology Center, following criteria are essential: high technology of drug manufacturing and quality excellence. Not only did KUP meet these standards, but is also accredited to have outstanding research performance on value-added raw material compounds. KUP is successful developing innovative drugs and commercializing it; We are constantly releasing new and value-added products such as anticancer drugs, hypertension drugs, and antidepressants.

Major ProductsName Indication Phase Classification

Clanza®CR Tabs. analgesic On Market New Controlled Release Drug Clavixin®Duo Caps. antithrombotic On Market New Combinational DrugCilostan®CR Tabs. antithrombotic In registration New Controlled Release Drug

R&D PipelineFormulation Study CMC Nonclinical Clinical Launch

NMELiverstar®Inj. ○ ○ ○

Docetaxel HS/BA Inj. ○

IMD

Clanza®CR Tabs. ○ ○ ○ ○ ○

Clavixin®Duo Caps. ○ ○ ○ ○ ○

Cilostan®CR Tabs. ○ ○ ○ ○ In registration

Unigril®CR Tabs. ○ ○ ○ ○

Gastin®CR Tabs. ○ ○ ○ ○

Aner®CW Tabs ○ ○ ○ ○

Levonazine®CR Tabs. ○ ○ ○

Unasc®Duo Tabs. ○

(NME : New Molecular Entites, IMD : Incrementally Modified Drugs)CONTACT US

Executive DirectorWon-Tae JungDepartment of Global R&D• Phone : +82-2-558-8612(Ext.201)• E-mail : [email protected]

ManagerJin-Seok JeonBD Licensing Team, Department of Global R&D• Phone : +82-2-558-8612(Ext.205) • E-mail : [email protected]

· Company Korea United Pharm. Inc.· CEO Duk-Young Kang· Specialty Manufacture, Marketing, & Sales Distribution of Pharmaceuticals and Other Healthcare Products· Location 25-23, Nojanggongdan-Gil, Jeondong-Myeon, Sejong, Korea· Homepage www.kup.co.kr

KUP is a global Pharmaceutical Companyall around world

Korea United Pharm. Inc.

Clanza®CR Tabs.

Clavixin®Duo Caps.

Korea United Pharm. Int’l Jsc.(Vietnam)

United Douglas Pharm. Inc.(USA)

Pharmaceutical

Pharmaceutical

3736

CONTACT US

SeungGoo RyuR&D Center / Team Manager• E-mail : [email protected]

Global pharmaceutical company committed in providing better quality of life for people. Kuhnil Pharm., Co.., Ltd.Kuhnil Pharm continues to strive to become an unique research-focused global company through development of innovative global biopharmaceuticals, DDS pharmaceuticals, and combination drug products in an effort to improve quality of life in patients.

Kuhnil has adopted an unique strategy of advancing into a new and niche areas of pharmaceutical development such as development of a world’s first approval of Omacor’s new indication called IgA nephropathy as well as developing new indication in the treatment of ulcerative inflammation of the small intestine for a novel GI drug. In 2005, Kuhnil participated in the NSCLC clinical program for an innovative biopharmaceutical, TheraCIM, subsequently collaborat-ing with Daiichi-Sankyo to initiate the phase 3 trial for gastric cancer in Korea and Japan in the 2nd half of 2012. In addition, Kuhnil has partnered with foreign CROs for the development of interferon-ß biosimilar. A subsidiary Com-pany, Penmix, specializes in penicillin formulation manufacturing. With the opening its new cGMP injectable facility, Kuhnil envisions the global CMO company reaching out abroad including Japan and EU, particularly, utilizing Kuhnil’s know-how in the areas of lyophillization process.

ProductsProduct Content Major Export Country

Antibiotics

Amocla/Amocla Duo Tab/Syr/inj

Amoxicillin Pot.clavulanate

Malaysia/Singapore/Vietnam* Export, 2011Y: 0.7m$

Tabaxin inj. Piperacillin sodium Tazobactam

Philippine* Export, 2011Y: 0.04m$

Piperacillin Inj. Piperacillin Sodium Japan* Export, 2011Y: 8.3m$

Pentacillin Inj. Ampicillin SodiumSulbactam Sodium

Japan/Vietnam/Philippine* Export, 2011Y: 14.0m$

Respiratory Pulmican Respule Budesonide micronized

Muscle relaxants Thiosina Tablet Thiocolchicoside Amorphous aescin

R&D PipelineArea of Research Pipeline Technology Indication Development Stage

Novel Drug DevelopmentKI 0401 Fermentation Antibiotic LaunchedKI 0501 Antibody Stomach Cancer/Lung cancer Phase 2/3

Bio-pharmaceuticals KI 0801 Recombinant Therapeutic Proteins Neurological Disorders Research

Modified Formulation/Improved Drugs

KI 1001 Insomnia Phase 3KI 1002 Improved Bioavailability Cancer ResearchKI 1003 Eating disorder ResearchKI 1007 Extended release Angina ResearchKI 1101 Extended release Musculoskeletal system disorder ResearchKI 1103 Genitourinary system ResearchKI 1104 Hair loss ResearchKI 1105 Chemosynthesis Sexual dysfunction Research

· Company Kuhnil Pharmaceutical Co.,Ltd· CEO Young Joong · Specialty Development, Manufacturing, and Distribution of Various Pharmaceutical

Products including Oral Dosage Forms, Injectables, Inhalers, etc.· Location OhSong B/D 27-11 Jung-Dong, Joong-Gu, Seoul, Korea, 100-120· Homepage www.kuhnil.com

Amocla/Amocla DuoTab/Syr/inj

Tabaxin inj.

Piperacillin Inj.

Pentacillin Inj.

Pulmican Respule

Thiosina Tablet

Global pharmaceutical company committed in providing better quality of life for people.

Kuhnil Pharm

Pharmaceutical

Pharmaceutical

3938

Contact Person: S,D. Kim / Rae Nah• Phone : +82-2-6006-7258 +82-2-6006-7259• E-mail : [email protected], [email protected]

Kwang Dong has been advancing in to a top-ranking pharmaceutical compa-ny in the world through thee establishment of the most advanced factories in Pyungtaek City.We were established in1963 and have been expanding our business operations around the world ever since. We have been enjoying an excellent reputation in technology over forty years because of the goods quality and dependability of our goods. We are one of leading pharmaceutical manufacturer in Korea having GMP factory for ETC, OTC, drink and nutrition supplement. So, we have been exporting to our pharmaceutical products (Finished products) to sell all over the world.

products1. Product Name: Bicalude Tablet (Bicalutamide 50mg) - Indication: Advanced prostate cancer in combination with LHRH analogue therapy or surgical castration - Visa Status Comment: Registered in Vietnam2. Product Name: Lenara Tablet (Letrozole 2.5mg) - Indication: Breast cancer - Visa Status Comment: Under registration in Philippine and Malaysia3. Product Name: Kwangdong Woohwang Chungsimwon Indication: Stroke, Hypertension, Palpitation, Mental anxiety, Acute. - Visa Status Comment: Registered in Japan and Vietnam4. Product name: Sedera ODF (Sildenafil citrate 50mg) - Indication: Treatment of erectile dysfunction5. Product Name: Cool strip ODF (Cetylpyridinium chloride 1.5mg) - Indication: Preventive treatment of pharyngitis, amygdalitis, stomatitis

R&D Pipeline

Category Product Name

Development Phases indicant dosage

form Development Type

Central Nervous System

KD501 Clinical test Phase II dementia oral License in from Elcomscience (Kor)Self developed

KD103 Developingdementia,

Alzheimer’s disease

considering Self developed

Metabolic disease KD101 Pre clinical obesity oral Self developed

Endocrine System KD802 Pre clinical short

stature Injection License in from Genexine (Kor) / joint research

Digestive trouble

Ramosetron ODF IND antinauseant

medicine oral / film Self developed

· Company Kwang Dong Pharmaceutical Co., Ltd.· CEO Choi, Soo Boo· Specialty Pharmaceutical business, Beverage Business· Location 1577-4 Seocho-Dong, Seocho-Gu, Seoul Korea· Homepage www.ekdp.com

CONTACT US

World’s leading human healthcare provider delivering health and happiness

Kwang Dong Pharmaceutical

Pharmaceutical

Pharmaceutical

3938

The First Pioneer in Korean Pharmaceutical R&D Products LG Life Sciences is Korea’s leading biopharmaceutical company. One of LG Group affiliate, demerged from LG Chem in 2002. LGLS is leveraging its proven R&D capabilities to develop world-class products, Factive®, the only US FDA approved nobel chemical drug, as well as Valtropin®, the first biosimilar approved by the EMEA and US FDA developed in Korea. LGLS is building a network of strategic alliances to extend its R&D and marketing reach.

ProductsFactive® - Fast Active, the most potent quinolone antibiotic in the world, commercialized in over 30 countries worldwideZemiglo® - A novel dipeptidyl peptidase IV (DPP IV) inhibitor for T2DM with good efficacy and safety profiles. Approved by the KFDA in June, 2012Eutropin® - The right choice for managing short stature recombinant human growth hormone with proven efficacy and safety since 1993Espogen® - Human recombinant erythropoietin, safe and effective treatment for anemia of chronic renal failureFollitrope® - Recombinant FSH, used in the treatment of female infertility in controlled ovarian hyperstimulation to induce the development of multiple follicles in a medically assisted reproduction program as well as anovulationHyruan Plus® - High molecular weight hyaluronic acid viscosupplement made by microbial fermentation for low side-effect, quality proven by EMEA and CE marking

R&D PipelineSR-hGH - The world’s first once-a-week human growth hormone, US NDA has been filed for adult and multinational phase III trials are finished for pediatric GHD Monoclonal Antibody Biosimilars - Enbrel, Humira and Avastin are biosimilars undergoing active development

1) Chemicals

Therapeutic Area Product Indication DS PC Clinical Trial NDAPI PII PIII

Infectious Factive IV Formulation ●

Metabolic

LC280391, etc. Type 2 Diabetes ●

Not Disclosed Anti-obesity ●

LC280126 Liver Embolism ●

CV LC231306 Atherothrombosis ●

Others

LC350189 Gout ●

LD02GIFRO Prokinetic ●

LD09RP Retinitis pigmentosa ●

2) Biologics

Class Product Indication DS PC Clinical Trial NDA MKTPI PII PIIIBiosimilar Espogen Anemia of CRF (global) ●

Long Acting SR-hGH GHD (global) ●

Antibody Biosimilar

Enbrel Rheumatoid Arthritis ●

Humira/Avastin Rheumatoid Arthritis ●

Vaccine Euforvac-hib D/T/P/HBV/M prevention ●

Jong-heon Won, ManagerBusiness Development Team• Phone : +82-2-6924-3233• E-Mail : [email protected]

· Company LG Life Sciences· CEO Il-Jae Jung· Specialty New chemical entity, biosimilar, Diagnositcs· Location LG Gwanghwamun Bldg. 92, Sinmunno-2ga, Jongno-gu, Seoul, Korea· Homepage www.lgls.com

Factive®

Declage®

Eutropin plus®

Zemiglo®

Euvax B®

Leading Global Life Science Company

LG Life Sciences

CONTACT US

Pharmaceutical

Pharmaceutical

4140

CONTACT US

Ochang Headquarters/Microbial Toxin R&D center• Phone : +82-70-8666-7520• Fax : +82-43-217-1557• E-Mail : [email protected]

Seoul Office• Phone : +82-2-3471-8319• Fax : +82-2-3471-8374

We are at the forefront of Korean biopharmaceutical industry, thanks to our excellent R&D capabilities based on our top-tier biotechnologists, and to our state-of-the-art operations and production facilities. Moreover, we are going to become a trailblazer in the field of biotechnology due to our passion and courage to embrace global challenges.

Since Botulinum Toxin Type A Neuronox (Neuronox is also being sold worldwide under different brand names such as Siax, Botulift, Cunox and Meditoxin) was launched in 2006, Medytox has shown a dramatic growth. Since 2009, we have ranked No. 1 market share in Korea and reached near 40% of market share. As more diverse indications are added, it appears that our market share would further increase. Our company has successfully developed the fourth botulinum toxin biopharmaceuticals in the world. We are exporting the products to about 50 countries, including Japan, Thailand, India and Brazil. We are also expecting to be a leading global biopharmaceutical company after entering the north America and EU Markets in 2016.

Main Products

1. Botulinum Toxin Type A product Medytox’s core business area is manufacturing of botulinum toxin type A biopharmaceuticals, Neuronox. It is

widely used not only in the cosmetic field, including facial wrinkle reduction, but also in the therapeutic field, for people with blepharospasm, cerebral palsy, etc.

2. Hyaluronic Acid Dermal Filler Medytox’s hyaluronic acid filler, Neuramis is currently being used in the field of cosmetics to smoothen deep and

fixed wrinkles on skin tissue Also, it is used as therapeutic agent for surgery and for treatment of arthritis. As a partner product, it could maximize a synergy effect along with Medytox’s core product Neuronox.

R&D Pipeline

Fueled by the success of Nueronox, we plan to perform a basic study for the development of innovative bio pharmaceuticals to heal degenerative arthritis, senile ocular disease, skin disease and cancer. We have strengthened base technology in protein engineering, antibody engineering and cell biology by recruiting talented personnel. As the first achievement, we have completed basic verification studies on degenerative arthritis and senile ocular disease (MT202 and MT401). It appears that they would enter into the pre-clinical phase in 2013. We plan to keep making investments with a long-term vision to be a global biopharmaceutical leader through development of innovative drugs.

· Company Medytox· CEO Jung Hyun Ho· Specialty Botulinum toxin products, Medical aesthetics, Bio-pharmaceuticals· Location 641-4 Gak-ri, Ochang-eup, Cheongwon-gun, Chungbuk 363-883, Korea· Homepage www.medytox.com

Toxin, Filler and Even more

Medytox

Nueronox®

Pharmaceutical

Pharmaceutical

4140

Bum Kyu, ShinGeneral Manager, Overseas Business Department• Phone : +82-2-3140-0673• Fax : +82-2-392-5315• E-Mail : [email protected]

Since its establishment in 1968, we, Samjin Pharm Co., Ltd. have strove our utmost efforts for producing qualitative pharmaceuticals and investing to re-search for the development of a new drugs with a philosophy of company that “Respect for human life”.

GMP Factory The manufacture of pharmaceutical products is the most important field of pharmaceutical industry as well as research and development. The production of pharmaceutical products, which demands the utmost precision and professionalism is a standard to evaluate the level of the pharmaceutical company. The manufacturing factory supports Samjin Pharmaceuticals’ advanced technology as well. In order to maintain the precision of manufacturing the pharmaceuticals, which is sensitive to all kinds of qualification, Samjin Pharmaceutical plant has been operated with the scientific and automatized system in all manufacturing processes.

ProductsSamjin Pharmaceutical is a comprehensive pharmaceutical company of developing, manufacturing and marketing finished products and APIs in the worldwide market. The representative products, “GEWORIN Tablet” has been occupied significant market share in analgesic market in Korea, and Samjin Pharmaceutical has continuously developed a marketing strategy for potential increase in sales and profits with high quality generic pharmaceuticals such as anti-platelet agent “PLATLESS Tablet (Clopidogrel 75mg Tablet)” and Clopidogrel Bisulfate (crystal form 1). Samjin Clopidogrel Bisulfate (crystal form 1) has excellent physico-chemical properties for the direct compression such as narrow particle size distribution, good flowability and good bulk density.

R&D Pipeline1. Development of Anti-HIV Agents : SJ-3366 SJ-3366(IQP-0528) is a unique and highly potent new nonnucleoside reverse transcriptase inhibitor of human

immunodeficiency virus type 1(HIV-1) that also inhibits HIV-2. Also its product is a novel candidate for a vaginal topical microbicides, currently being performed with preclinical study against formulation both a gel and an intravaginal ring.

2. Development of Anticancer Agents : SJ-3902 SJ-3902 Series is a novel, highly potent and safe anticancer agent with unique mechanism of action and

chemical structure suggesting the first member of new pharmacology class of tumor cell cycle interrupt on oncology field. The compound exhibits microtubule-interfering(G2/M), apoptosis, and inhibition of angiogenesis.

3. Development of anti-influenza virus The derivatives of benzimidazole and coumarin as extracts of plants was identified a potent efficacy of

influenza virus A and B, low cytotoxicity. These compounds inhibits the bind to haemagglutinin and influenza viruses, also neuraminidase of viruses

4. Development of therapeutic agent for neurodegenerative brain disease : SJ-2249 A potential therapeutic candidates to target brain neurodegeneration by repressing chronic microglial

activation and inhibition of acetylcholinesterase

· Company Medytox· CEO Jung Hyun Ho· Specialty Botulinum toxin products, Medical aesthetics, Bio-pharmaceuticals· Location 641-4 Gak-ri, Ochang-eup, Cheongwon-gun, Chungbuk 363-883, Korea· Homepage www.medytox.com

· Company Samjin Pharmaceutical Co., Ltd.· CEO Sung Woo, Lee· Specialty Manufacture, Marketing and Distribution of Pharmaceutical Products (Finished Products and APIs)· Location 338-8, Seogyo-Dong, Mapo-Gu, Seoul, Korea· Homepage www.samjinpharm.co.kr

For the Health Life and Fruitful Future

SAMJIN Pharmaceuticals

CONTACT US

Pharmaceutical

Pharmaceutical

4342

Innovative Specialty Pharmaceutical Company

Samyang Biopharmaceuticals Corporation

CONTACT US

Oversea Sales Jae-Wook JooTeam Leader, Sales Team• Phone : +82-2-740-7163• E-Mail : [email protected]

Business developmentHee-Jeong BaeManager, Business development• Phone : +82-2-740-7262• E-Mail : [email protected]

Samyang Biopharmaceuticals Corporation is focusing its efforts on healthcare as its core strategic business of the 21st century.

Samyang Biopharmaceuticals Corporation, with its central research center is engaged in the development and marketing of novel drug delivery systems and medical devices.

Samyang Biopharmaceuticals Corporation is developing proprietary and unique core technologies for the development of world class novel drug delivery systems.

Main ProductsPharmaceuticals

Category Products Active Ingredient Indication

Injection

Genexol® Inj. Paclitaxel Anti-cancer

Genexol-PM® Inj. Paclitaxel Anti-cancer

Nanoxel®-M Inj. Docetaxel Anti-cancer

Pemed® Inj. Pemetraxed Anti-cancer

Zolenic® Inj. Zoledronic Acid Bone metasis

Emastop® Inj. Ramosetron Anti-emetics

Trans-dermal

Rheumastop® Plaster Diclofenac Diethylamine NSAIDs

Tulobuterol Patch Tulobuterol Bronchodilator

Fentaderm® Patch Fentanyl Severe Pain

Rivastigmine Patch Rivastigmine Anti-ParkinsonAnti-Alzheimer

Oral Emestop® FD Tab. Ramosetron Anti-emetics

Medica

Category ProductsSuture Synthetic Absorbable Suture (PGA, PDO, PGLA, PGCL etc.)

Implantable Mesh Hernia Mesh, OBGY Mesh, Dental MeshWound Closure Surgical Sealant, Hemostat

R&D PipelineCategory Technology Description Products Development Status

Injection

Polymeric Micelle Genexol-PM®

Nanoxe®-MMarketed

Registration

Polymeric Nano-Particle Docetaxel-PNPVoriconazole-PNP

Clinical (Phase I)Clinical (Phase I)

Polymeric Micro-Particle hGH-PMP SR Non-clinical

Trans-dermalTDS

(Transdermal DrugDelivery System)

Capsaicin Clinical (Phase II)Fentaderm® RegistrationRivastigmine BE study

Oral BA enhancing Celecoxib Non-clinical

· Company Samyang Biopharmaceuticals Corporation.· CEO Cheol-Ho Kwak· Specialty Oncology, Drug Delivery System Technology · Head Office 263 Yeonji-dong, Jongno-gu Seoul 110-725· Homepage www.samyangbiopharm.com

Pharmaceutical

Pharmaceutical

4342

CONTACT US

Mr. Dwight You, Senior Manager• Phone : +82-2-740-7915• E-Mail : [email protected]

Samyang Genexbio has solidified its reputation as a quality manufacturer with Worldwide GMP system and facility.

Soon to be united with Samyang Biopharmaceuticals within Samyang Group, the product portfolio is now more complete than ever. Samyang now provides its customers an excellent selection of active ingredients and finished products in the forms of injections, patches, and capsules.

- Speciality Active Pharmaceutical Ingredients[APls]- Speciality Injectables [Finished form]- Contract Manufacturing Service [Liquid & Lyophilized Injectables]- Strength in Plant Cell Culture, Fermentation, and Purification- Strong investment into Pharmaceutical Research & Development- Full cGMP Compliance

GMP Certifications from Foreign Health Authorities

Paclitaxel APIHungary(2004)

EU/Germany(2004,2008,2011)Iran(2009)

Japan(2010)Docetaxel API EU/Germany(2011)

Oncology injectables(Sterile product)

Iran(2009)EU/Germany (2010, 2012)

Japan(2010)Patch product Australia(2011)

Product Pipeline

APIAnti-cancer

Paclitaxel, Docetaxel, CabazitaxelEpothilone, Ixabepilone

Everolimus/Temsirolimus (under development)Antibiotic Vancomycin-HCl

Immunosuppressant Tacrolimus, Sirolimus

Finished Product(Oncology)

Paclitaxel, Docetaxel, OxaliplatinGemcitabine, Ramosetron

Pemetrexed, Zoledronate (under development)Finished Product(Other injectable)

Iron-sucroseOctreotideLAR, ExenatideLAR

Finished Product(Patches)

Diclofenac, Tulobuterol, RivastigmineNicotine, Capsaicin, Fentanyl

Finished Product (Capsule) Tacrolimus

Contract ManufacturingOncology injectables (Solution/Lyophilized)

Patch products

Products and ServicesSamyang Genexbio offers both active pharmaceutical ingredients and finished products as well as contract manufacturing service.

· Company Samyang Genexbio Corporation· CEO Dr. Hojoon Choi· Specialty Oncology API and Injections, GMP Manufacturing· Head Office 31, Jongro-33-gil, Jongno-gu, Seoul, 110-725, South Korea· Homepage www.samyanggenexbio.co.kr

Oncology API and Injections, GMP Manufacturing

Samyang Genexbio Corporation

Pharmaceutical

Pharmaceutical

4544

pharmaceutical company with the Top-levelsales of prescription drugs in the Surgery market

Shin Poong Pharm.Co.,Ltd

CONTACT US

Contact InformationPaul Choen, Director• Phone : +82-2-2189-3471• E-mail : [email protected]

Shin Poong is the pharmaceutical company with the No. 1 sales of prescription drugs in the Surgery market.Under the management philosophy of ‘for the health of the people’, Shin Poong Pharm.Co.,Ltd specializes in manufacturing remedy drugs with sincere efforts put into producing every single tablet of life-saving drugs ranging from ingredients to finished products based on our state-of-the-art manufacturing facilities and quality assurance system. We are committed to realizing the spirit of Shin Poong 3V(Vision,Venture and Victory) with top- notch competitiveness based on in-house ingredient synthesizing technologies obtained through rigorous R&D efforts and to further developing the company into the one that receives confidence from our customers and that contributes to promoting the wellbeing of human beings.

In 2011, Shin Poong developed PYRAMAX® in cooperation with Medicines for Malaria Venture and approved by Korean FDA. PYRAMAX® is the first artemisinin combination therapy to receive an Article 58 positive scientific opinion from EMA for treatment of both strains of malaria : P.falciparum and P.vivax, in adults and children over 20kg and was listed on WHO prequalified medicines in may 2012.

Main ProductsName Indication Phase Classification

Pyramax Tab. Anti-malaria On Market NMELoxfen CRTab Analgesic On Market IMDHyal Forte Inj Arthritis On Market GenericClamoxin Tab. Anti-biotics On Market Generic

Medi-curtain Inj. Adhesion Barrier On Market Medical device

R&D Category Products Indication Stage

NME

Pyramax Tab. Anti-malaria Launch(Korea) Registration(EMA)Pyramax Gran. Anti-malaria Phase 3(Asia, Africa)

SP-8203 Anti-stroke Pre-clinic(US/Korea)KR-35454 Anti-osteoporosis Pre-clinic(Korea)

IMD

Loxfen CR Tab. NSAIDs Launch(Korea)Loxfen Inj. NSAIDs NDA(Korea)

Bontil plus-M Anti-osteoporosis NDA(Korea)Hyal one Anti-osteoporosis Pre-clinic(US/Korea)

Derma filler Derma filler Pre-clinic(US/Korea)-Medical device

※ New Molecular Entity, Incrementally Modified Drug

Company SHIN POONG PHARM.CO.,LTDCEO CHANG KYUN KIM Specialty Manufacture and Sales of the pharmaceutical productsHead Office 748-31 YOKSAM-DONG, KANGNAM-GU, SEOUL, 135-925, KOREAHomepage www.shinpoong.co.kr

Hyal Forte inj.

Pyramax Tab.

Pharmaceutical

Pharmaceutical

4544

CONTACT US

Haein Shin

Duncan TaylorSenior Director, Business DevelopmentSK Life Science, Inc.• Phone : +1-201-421-3842• E-mail : [email protected]

Senior Manager, Business DevelopmentSK Biopharmaceuticals Co., Ltd.• Phone : +882-2-2121-5353• E-mail : [email protected]

SK Biopharmaceuticals is a development-stage pharmaceutical company spun out from SK Holdings, the third-largest conglomerate in South Korea.SK Biopharmaceuticals focuses on discovery and development of new drugs as well as providing custom services for the manufacture and sales of active pharmaceutical ingredients and intermediates of drugs for major companies, in the factories that have been newly approved in Korea for current Good Manufacturing Practices of active pharmaceutical ingredients.SK Biopharmaceuticals, through its affiliate SK Life Science, leads all Korean pharmaceutical companies with 13 authorized INDs in the U.S. SK Biopharmaceuticals has a preclinical research and development center located in Daejeon, South Korea, and SK Life Science, its business development and clinical research center in New Jersey, for the clinical development of its assets in the areas of epilepsy, neuropathic pain, depression, irritable bowel syndrome, and Parkinson’s disease.The Custom Manufacturing Service Business manufactures active pharmaceutical ingredients for other pharmaceutical company customers. These customers have recognized the quality of the products, the operational efficiency provided by the Korean FDA-approved manufacturing facility in Daejeon, Korea, and technologies proprietary to SK Biopharmaceuticals, such as continuous flow synthesis, low temperature reactions, and catalytic conversions, that differentiate the company from other chemical suppliers.

R&D PipelineProducts Indications Development Stage

Diazepam Nasal Spray Acute Repetitive Seizures Pre-NDA Meeting StageCarisbamate (YKP509) Epilepsy, Infantile Spasm (Orphan Designation) Phase 3YKP3089 Epilepsy, Neuropathic Pain, Bipolar Disorder Phase 2SKL11197 Neuropathic Pain Phase 2YKP10811 Chronic Constipation, Irritable Bowel Syndrome Phase 2SKL-DEP Depression Phase 1SKL-N05 Narcolepsy, Drug Addiction Phase 1YKP1447 Schzophrenia Phase 1SKL-PD Parkinson’s Disease, Neuroprotection Phase 1SKL-NP2 Neuropathic Pain PreclinicalSKL-A4R Alzheimer’s Disease PreclinicalSKL-PSY Bipolar Disorder PreclinicalSKL2020 Restenosis DiscoveryPain Project Pain DiscoveryAD Project Alzheimer’s Disease DiscoverySchizophrenia Project Schizophrenia DiscoveryMS Project Multiple Sclerosis DiscoveryALS Project Amyotrophic Lateral Sclerosis Discovery

· Company SK Biopharmaceuticals Co., Ltd.· CEO Christopher C. Gallen, M.D., Ph.D.

· Specialty Drug Development Business developing innovative new drugs to treat central nervous system disorders and Custom Manufacturing Business producing pharmaceutical intermediates and active pharmaceutical ingredients

· Location 99 Seorin-dong, Jongro-gu, Seoul 110-110, Korea· Homepage http://www.skbp.com

For the healthy future of our customers

SK Biopharmaceuticals

Pharmaceutical

Pharmaceutical

4746

The life science part of SK Chemicals is recording continuous sales expansion such as Sunpla the domestic new drug No.1 anti-cancer medicine, Trast the ar-thritis medicine of domestic market share ranking 1st, Joins the domestic natural new drug No.1, etc.

Main ProductsProduct Information

Sunpla Inj. (3rd generation Cisplatin) anti-cancer agent* The 1st Korean new chemical entity

Trast patch (Piroxicam) Patch formulation with anti-inflammatory

Joins (Clematis mandshurica, Trichosanthes killilowii, Prunella vulgaris ext)

Cartilage protective agent*The 1st Korean new herbal drug

Mvix (Mirodenafil) Treatment of erectile dysfunction (ED)

R&D Pipeline

SK Chemicals focuses on developing new chemical entities, herbal and biopharmaceutical drugs in therapeutic areas with high unmet medical needs.

Product InformationNCE 401 (RIF, Radio-induced Fibrosis agent) New Chemical Entity, In preclinical study

NCE 402 (type2 diabetes agent) New Chemical Entity, in preclinical study at USA.

NCE 403 (BPH, Benign prostatic hyperplasia agent) New Chemical Entity, in Preclinical study at USA

NBP 601 (anti- Heamophilia agent, 4th generation FactorVIII) Bio-Better, in Clinical study at USA with CSL

SID 710 (anti-dementia patch, Rivastigmine) IMD, in Registration at EU

SID 820 (anti-gastric ulcer agent, Esomeprzole freebase) IMD, in Registration at EU

· Name SK Chemicals Co. Ltd.· CEO Chang Geun, Kim·Specialty specialty chemicals and life science business · Location 686,Sampyeong-dong, Bundang-gu, Seongman-si, gyeonggi-do, 463-400 Korea · Homepage www.skchemicals.com

Developing new chemical entities, herbal and biopharmaceutical drugs

SK Chemicals

US BRANCH

400 kelby St. 17th Fl. Fort Lee,NJ 07024Joon won, Park• Phone : +1-201-753-0300• E-mail : [email protected]

CONTACT US

Name : Sojin, Jung Associate research Scientist• Phone : +82-2-2008-1972 • E-Mail : [email protected]

Pharmaceutical

Pharmaceutical

4746

“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing service of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliance with cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization.

Main Products1. Custom Manufacturing 1) New Drug APIs & Intermediates 2) GMP-Oligonucleotides (for RNA therapeutics)

2. Generic APIs & IntermediatesWith highly experienced technical teams and synergistic collaboration with a parent company, Dong-A Phar-maceutical, ST Pharm extends the product pipelines to generic APIs and intermediates with supportive DMFs and high-spec quality control required to timely enter domestic and global market.

[Table 1] Products List (selected)

Category Products Customer Indication/Stage

New Drug APIs

HCV drug Originator (Worldwide) HCV/Phase 3HIV drug Originator (Worldwide) HIV/MarketedHIV drug Originator (Russia) HIV/Marketed

Oligonucleotide Originator (Worldwide) Oncology/Phase 2

Pharmaceutical Intermediates

Chiral epoxide Originator (Worldwide) HIV/MarketedChloro-(L)-sugar Originator (Worldwide) HBV/Marketed

Nucleoside monomers US/EP/JP Various RNA therapeutics/Clinical

Generic APIs

Stavudine ROW/EU HIV/MarketedTerizidone S.Africa/Germany/CIS Tuberculosis/Marketed

Atorvastatin Domestic/JP/ROW Hyperlipidemia/MarketedClopidogrel Domestic/ROW Anticoagulant/MarketedOlmesartan JP/ROW Hypertension/Marketed

R&D Pipeline[Table 2] R&D Pipeline (selected)

Category Project Goal

CMOAntibiotics Commercial in 2013

Gastritis therapeutics for clinical trialDiabetes therapeutics Commercial in 2014

New DrugAnticancer (CRPC) Pre-clinical in 2014

HIV Pre-clinical in 2014

Generic APIs

Anticancer Released in 2013MRI contrast media Released in 2014

HBV Released in 2015COPD Released in 2016

· Company ST Pharm Co., Ltd.· CEO Geun-Jho Lim· Specialty CMO (New Drug APIs & Intermediates), Generic APIs, Oligo APIs and New Drug Development· Location 7F MSA Bldg., 891-43, Daechi-dong, Gangnam-gu, Seoul, Korea· Homepage http://www.stpharm.co.kr

World Leader in API Custom Manufacture

ST Pharm

CONTACT US

Seong-Soo OhChief ResearcherR&D Planning TeamR&D center• Phone : +82-31-488-1409• E-mail : [email protected]

Pharmaceutical

Pharmaceutical

4948

CONTACT US

Junhee, Lee/ Head of Department• Phone: +82-2-799-0072• E-mail: [email protected]

Minyoung, Hong/ Manager• Phone: +82-2-799-0161• E-mail: [email protected]

Jungkeun, Park/ Staff• Phone: +82-2-799-0163• E-mail: [email protected]

Taejoon Pharm Co., Ltd. is a pharmaceutical company with 34-year experience and the first company worldwide to possess technological power in three major areas: the development of new drugs, ophthalmologic drugs and contrast media.

Main ProductsOphthalmic Solution▪XALOST (API: LATANOPROST) - Release date: May 2005. - Indication: Reduction of intraocular pressure of the following diseases open-angle glaucoma, chronic angle-closure glaucoma, ocular hypertension.▪COMBISOPT (API: DORZOLAMIDE HCL, TIMOLOL MALEATE) - Release date: Feb 2011. - Indication: For the treating of disorders such as glaucoma or high eye pressure. Combisopt lowers high pressure in the eye, a problem typically caused by the condition known as open-angle glaucoma.▪TJ CYCLOSPORINE (API: CYCLOSPORINE) - Release date: After patent expiry. - Indication: Increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Contrast media▪IOBRIX Inj. (API: IOHEXOL) - Release date: Jan 2002. - Indication: Myelography, angiography, urography, contrast enhancement of computerized tomography.▪IVERSENSE Inj. ( API: IOVERSOL) - Release date: Nov. 2008. - Indication: For cerebral angiography and peripheral arteriography, contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography.▪MRbester Inj. (API: GADOPENTETATE DIMEGLUMINE) - Release date: Feb. 2004. - Indication: MR imaging for the whole body excluding the heart, central nervous system incluing the brain,spine and associated tissues in adults and pediatric patients. (2 years of age and older)

GMP Certification ListNo. GMP Facility Year

1 KGMP Sterile ophthalmic solution 20052 EU GMP Sterile ophthalmic solution 20093 Anvisa GMP Sterile ophthalmic solution 20104 Actavis Audit Vendor audit for sterile ophthalmic solution 2010

R&D PipelineProduct name Indications Current status

New quinolone ophthalmic solution Bacterial conjunctivitis Pre-clinical trialNew improved drug for dry eye Dry eye Ongoing pre-clinical trial phase 3Quinolone new improved drug 1 Bacterial conjunctivitis Ongoing pre-clinical trial phase 3Quinolone new improved drug 2 Bacterial conjunctivitis Ongoing pre-clinical trial phase 3New colon-cleansing drug for colonoscopy prep Colonoscopy preparation Ongoing pre-clinical trial phase 3Laxative for constipation Constipation Ongoing pre-clinical trial phase 3Gastritis combination drug Gastritis Ongoing pre-clinical trial phase 3

· Company TAEJOON PHARM. CO., LTD.· Co-CEO Tae Young, Lee/ Joon Youb, Lee· Specialty Ophthalmic solution, Contrast media.· Location 657-87 Hannam-dong, TAEJOON Bldg., Yongsan-gu, Seoul, Korea· Homepage www.taejoon.co.kr

Leading Biotech Company for Better Life

Taejoon Pharm

XALOST

Pharmaceutical

Pharmaceutical

4948

Leading biotechnology companytargeting cardiovasucular disease, cancer, and immune-related disorders

VM BioPharma (ViroMed)

CONTACT US

Youngtae Hong Team Manager, Strategic business• E-mail : [email protected]

VM BioPharma, one of the most active drug development companies among world’s small-cap biotech entities, was established in 1996 and has been listed on the KOSDAQ stock exchange (ticker #: 084990) since 2005. The Com-pany is focusing on the development of innovative medicines in the areas of cardiovascular disease, neuropathy, cancer and immune disorder.

Main ProductsProduct Target Disease Technology Country Development Stage

VM202-PAD Critical Limb Ischemia DNAUSA

Phase II(Patient Enrollment)Korea

China

VM202-DPN Diabetic PeripheralNeuropathy DNA

USA Phase II(Patient Enrollment)Korea

VM202-CAD Chronic RefractoryMyocardial Ischemia

DNA + Noga XP USA Phase I/II(IND Approved)

DNA + direct injection Korea Phase I (Completed)Phase II/III (Planned)

VM501 Thrombocytopenia Protein China Phase III(Patient Enrollment)

VM206 Breast Cancer DNA+Virus Korea Phase I(Patient Enrollment)

VM202 – DNA therapeutics inducing angiogenesis and nerve regenerationVM202 is a DNA-based medicine for the treatment of ischemic cardiovascular diseases such of coronary artery disease and peripheral artery disease. It is designed to express two isoforms of hepatocyte growth factor (HGF), which induces the formation of new blood vessels when injected into the ischemic sites. These new collateral vessels will increase blood flow and tissue perfusion, thereby effectively treating ischemia. VM202 also treats diabetic peripheral neuropathy (VM202-DPN) by stimulating the growth and regeneration of nerve cells. For VM202 to enter the global market, the company is carrying out multinational late stage clinical trials in late stages in the US, China, and Korea.

Selected References: Senda AD et al., Annals of Neurology, Submitted / Henry TD et al., Gene Therapy 2011;18:788-794 / Gu et al., The Journal of Gene Medicine, 2011;13:602-610,Saeed M et al., Cardiovasc Revasc Med. 2011;12:111-122 / Pyun WB et al., Gene Therapy 2010;17:1442-1452, Saeed M et al., Radiology 2008;249:107-118 / Cho KR et al., Eur J Cardiothorac Surg 2008;34:857-863, Carlsson M et al., American Jour of Physiology 2008;295:H522-532

VM501 – Protein Therapeutics for ThrombocytopeniaVM501 is a re-engineered form of interleukin 11(IL-11) targeting chemotherapy-induced thrombocytopenia (CIT). It has been shown to induce an increase in the number of blood platelets. In Phase I and Phase II clinical trials performed in China, significant therapeutic effects were shown without severe adverse events.Phase III clinical trial is ongoing in 18 hospitals in major cities of china including Beijing, Tianjin and Dalian in China.

Selected References: Shikai Wu, Support Care Cancer, In Press / Jung Y, Biochemical and Biophysical Re-search Communications 2011;405:399-404

VM206 – Therapeutic Cancer Vaccine.VM206 is a therapeutic cancer vaccine that has potential applications for breast, ovarian, and pancreatic cancers. The pre-clinical efficacy data was published in Gene Therapy (2008, 15, 1351-1360) and Phase I clinical trial is currently ongoing in Korea.

· Company VM BioPharma· CEO Kim Yongsoo· Specialty

1) DNA/protein-based biopharmaceuticals 2) Phytotherapeutics (botanical drugs/nutraceuticals)

· Location Bldg 203, Seoul National University, # 599 Gwanak-ro, Gwanak-gu, Seoul, Korea· Homepage www.viromed21.com

Pharmaceutical

Pharmaceutical

Best Partner Best Yuhan

Yuhan Corporation

Eqipped with the state-of-the-art cGMP manufacturing facilities and extensive research capabilities, Yuhan is growing into a global pharmaceutical company offering one stop services from R&D to commercial production of intermediates, APIs, and finished products.

Yuhan has undergone successful audits by many international regulatory agencies such as the US FDA, the EU EMA/EDQM, the Australian TGA, and the Japanese PMDA. Yuhan’s overseas’ business activities include:

- New drug development projects with multinational partners. - Developing and optimizing cost effective synthetic processes for APIs and intermediates.

Yuhan is committed to deliver the best medicines to the world for improving the health and quality of human life. Beginning with the out-licensing to China of Yuhan’s ‘Revanex’, the world’s first acid pump agonist, Revanex is now supplied world-wide to markets in India and Southeast Asia. Yuhan is continuously expanding its overseas markets with finished

ProductsProduct/Project Indication Feature & Strength

Revanex Gastritis Feature & StrengthNCE drug, NDA (2007), World-first acid pump antagonist (APA)

YH4808 GERD NCE drug, on phase 2, 2nd generation APA. Fast onset-time and cleaner adverse effect profile than current PPI

YH12852 IBS NCE drug, expected to fulfill unmet medical needs for IBS treatment, Comparative advantage of efficacy and safety to current market players

R&D Pipeline

CONTACT US

Head Quarters49-6, Daebang-dong, Dongjak-gu, Seoul, 156-754, Korea• Phone : +82-2-828-0181• Fax : +82-2-828-0300

· Company Yuhan Corporation· CEO Yoon Searb, Kim· Specialty Pharmaceutical · Location Daebang-dong, Dongjak-gu, Seoul, Korea· Homepage http://www.yuhan.co.kr/Eng/index.asp

50

Supplement“ The global growth of Korean pharmaceutical industry ”

Supplement

Supplement

5352

1.Products expected to exportCompany Product name Active Ingredient Indication Category Expected country Note

Ahngook Pharm

Synatura syrupDried Ivy leaf ext. 262.5mg + Coptis Rhizome Butanol Dried ext. 87.5mg among 100ml

- Relief of cough and sputum due to acute respiratory infection and chronic inflammatory bronchitis

Prescription (ETC)

Global(Specially EU)

-

Anycough Cap. Theobromine 300mg- Relief of cough symptoms caused by postnasal drip, gastroesophageal reflux disease, bronchiectasis and chronic bronchitis

Prescription (ETC) Global -

Anytin SR Tab. Trimebutine maleate 300mg Relaxation of digestive system Prescription (ETC) Global -

Xaltrin XL Tab. Alfuzosin HCl 10mg- Treatment of the functional symptoms of benign prostatic hypertrophy (BPH)- Adjuvant therapy for catheter in acute urinary retention related to BPH

Prescription (ETC) Global -

Anyfen syrup Dexibuprofen 12mg among 1mL - Fever by acute respiratory infection Prescription

(ETC) Global -

BCWORLD Pharm

Mepem Inj. 1g Meropenem 1g Antibiotics Prescription Medicine

US, EU, Middle East

-

Sinraci Inj. 500mg Imipenem, Cilastatin sodium Antibiotics Prescription

Medicine -

Vitamin Inj. Tamiflumate Well-being products Prescription Medicine -

Morphine Sulfate Inj. Morphine Sulfate Narcotics Prescription

Medicine -

BC Atorvastatin Tab. Atorvastatin Calcium Lipid-Lowering agents Medicine -

Remiba Inj. Remifentanyl HCl Narcotics Medicine -

Binex

human Growth Hormone Somatropin Growth Hormone Deficiency Biological

Product World -

Biscan tablet Bacillus polyfermenticus n.sp.

Normalization of bowel movement, abdominal inflation, loose feces, constipation, abdominal fermentation in intestine

Probiotics US, EU, etc. -

Biscan-N tablet, powder Bacillus Licheniformis

Normalization of bowel movement, abdominal inflation, loose feces, constipation, abdominal fermentation in intestine

Probiotics US, EU, etc. -

BioneerSAMiRNA-Survivin Solid cancer siRNA drug US, EU -

SAMiRNA-COPDtarget genes COPD(chronic obstructive pulmonary disease) siRNA drug US, EU, CN -

Boryung Pharm

Kanarb Fimasartan Hypertension Prescription medicine Global -

D-Taxel Docetaxel Oncology Prescription medicine

ASIA, LATIN AMERICA, MIDDLE EAST

-

DOXORUBICIN DOXORUBICIN Oncology APIEU, JAPAN, CHINA,AMERICA

-

PITAVASTATIN PITAVASTATIN Hypertension APIEU, JAPAN, CHINA,AMERICA

-

Chon Kun Dang

TacroBell Tacrolimus Immunosuppressant Prescription Medicine Worldwide -

Cipol N Ciclosporin Immunosuppressant Prescription Medicine Worldwide -

My-Rept Mycophenolate mofetil Immunosuppressant Prescription

Medicine Worldwide -

Gemtan Gemcitabine Anti-cancer Prescription Medicine Worldwide -

Belotaxel Docetaxel Anti-cancer Prescription Medicine Worldwide -

CJ cheiljedang

Citopcin inj. Ciprofloxacin Infection Antibiotics - -

Tapocin inj. Teicoplanin Infection Antibiotics - -

CJ Vancomycin inj. Vancomycin Infection Antibiotics - -

Epokine inj. Erythropoietin Anemia Biologicals - -

Leukokine inj. Filgrastim Neutropenia Biologicals - -

Supplement

Supplement

5352

Dae Hwa Pharm

Resnalin patch TulobuterolRespiratory distress caused by airway obstruction of bronchial asthma, acute

bronchitis, chronic bronchitis, or emphysemaPrescription Medicine US, EU, etc. -

Aceren cap. Diacerein Rheumatoid arthritis, osteoarthritis Prescription Medicine US, EU, etc. -

Almetamine tab.Betamethasone,

Dexchlorpheniramine maleate

Urticaria, hay fever, allergic rhinitis, drug hypersensitivity reaction, chronic bronchial asthma, atopic dermatitis, eczema, contact

dermatitis, allergic conjunctivitis

Prescription Medicine US, EU, etc. -

Bidica tab. Biphenyl dimethyl dicarboxylate

Chronic persistent and active hepatitis that is associated with a high SGPT level or drug-

induced high transaminase levelPrescription Medicine US, EU, etc. -

Protase tab. Bromelain, Crystallized Trypsin

Fracture, sprain, internal, external and incarcerated hemorrhoid after proctoptosis and

a hemorrhoidal surgeryOTC Product US, EU, etc. -

Daewon pharm

Pelubi Tab. Pelubiprofen NSIADs Prescription Medicine US, EU -

Oramin Cap. Multivitamins Multivitamin OTC Product US, EU -

Daewoong Pharm

URSA Ursodeoxycholic acid Hepatobiliary Diseases OTC/ETC Worldwide -

Meropenem Meropenem Antibiotics ETC Worldwide -

Easyef rhEGF Diabetic foot ulcer, traumatic wound, skin ulcer Biological Worldwide -

Caretropin Somatropin Growth hormone deficiency Biological Worldwide -

Luphere Leuprolide acetate Prostate cancer, Breast cancer ETC Worldwide -

Dong-A Pharm

Zydena Udenafil Erectile dysfunction Prescription medicine EU, etc. -

Monotaxel Docetaxel Anti-cancer Prescription medicine EU, etc. -

- Epirubicin Anti-cancer API EU, etc. -

Closerin Cycloserine Anti TB Prescription medicine China, etc. -

Gonadopin Follitropin FSH Prescription medicine etc. -

Green Cross Corp.

GreenGene F inj.Beroctocog alfa (Blood coagulation factor VIII,

recombinant)

For the prevention and control of bleeding episodes and preoperative management in

Hemophilia ABiological Product

USA, Europe, Latin America,Asia Middle

East, etc-

GC FLU inj.

Purified Inactivated Influenza Virus Antigen Type A (H1N1)Purified Inactivated Influenza Virus Antigen Type A (H3N2)Purified Inactivated Influenza

Virus Antigen Type B

For the Prophylaxis against Influenza Biological Product

USA, Latin America,

Asia, Middle East, etc

-

Hunterase Idursulfase-ßFor patients with Hunter Syndrome

(Mucopolysaccharidosis II, MPS II) as an enzyme replacement therapy

Biological Product

USA, Europe, Latin America,Asia, Middle

East, etc-

Hanlim Pharm

DAGES CAP Pepsin etc. Polyenzymatic digestant OTC Product Vietnam,Chile etc. -

LODIEN TAB s-AmlodipineNicotinate Antihypertensives Prescription

MedicineVietnam,Chile etc. -

HYALURON EYE DROPS Hyaluronate Na Epithelial protector

of cornea& conjunctivaPrescription Medicine US,India etc. -

NASATIVENASAL SPRAY

Mometasonefuroate Antiallergics Prescription

Medicine US,India etc -

TROPIN INJ. Dopamine HCI Cardiac drugs Prescription Medicine

Vietnam,Chile etc. -

Ilyang Pharm

SUPECT Cap. radotinib Ph(+) chronic myeloid leukemia (CML) in chronic phase (CP) or accelerated phase (AP)

prescription medicine - -

Noltec tab Ilaprazolegastric ulcer, duodenal ulcer, gastroesophageal

reflux disease, non-erosive reflux disease

prescription medicine - -

WONBI-D LIQUID Korea Ginseng Improves Health OTC Product EU -

Sol + LIQUID Taurine, Multi Vitamin Improves performance Beverage/Energy Drink EU/ASIA -

Aldrin Suspension Almagate 1.5G/1G Antacid action OTC Product EU/ASIA -

Supplement

Supplement

5554

Kolmar Korea

ZERO-X Cap.

Orlistat Anti-obesity Agents Prescription Medicine

EUSouth America

Asia-

GLITOL Tab. Miglitol Anti-Diabetics Prescription Medicine

EUAsia

Middle East-

MAXFORGE Tab. Valsartan and Amlodipine Antihypertensive Prescription

MedicineAsia

Middle EastAfrica

-

Taminal Cap. Tamsulosin HCl BPH Prescription Medicine

AsiaMiddle East

Africa-

Denti-lid Cap.Titrated extract of the

unsaponifiable fraction of Zea mays L.

Periodontal Disease OTC Product(Lidcaps)

AsiaMiddle East

Africa-

Korea United Pharm

Clanza CR Tabs. Aceclofenac 200mg analgesicIMD(New Controlled

Release Drug)EU, South America launched

Clavixin Duo Caps. Clopidogrel 100mg / Aspirin 75mg antithrombotic

IMD(New Combinational

Drug)US, EU, South

America launched

Cilostan CR Tabs. Cilostazol 200mg antithromboticIMD(New Controlled

Release Drug)US, EU, South

AmericaIn

registration

Kuhnil pharm

Caspofungin for Inj. 70 mg Caspofungin acetate Antifungal Agents Prescription

Medicine worldwide -

Tigecycline for Inj. 50 mg Tigecycline Antibiotics Prescription


Gadopentatic Inj. Gadopentatic acid MRI contrast Prescription Medicine worldwide -

Alprostadil Inj. Alprostadil Vasodilators Prescription Medicine worldwide -

Somatostatin for Inj. 3 mg Somatostatin acetate Hormone & Synthetic Agents Prescription


Kwang dong pharm

Bicalude Tablet Bicalutamide 50mg anti-cancer Prescription Medicine

all over the world -

Lenara Tablet Letrozole 2.5mg anti-cancer Prescription Medicine


Woohwangchungsimwon

variety herbal ingredient stroke, hypertertension OTC Product all over the

world -

Ketoprofen ketoplus cataplasma 60mg degenerative arthritis OTC Product all over the

world -

KD-fen Diclofenac 120mg Analgesia, anti-inflammatory OTC Product all over the world -

LG Life Sciences

Bicalude Tablet Bicalutamide 50mg anti-cancer Prescription Medicine


Lenara Tablet Letrozole 2.5mg anti-cancer Prescription Medicine


Woohwangchungsimwon

variety herbal ingredient stroke, hypertertension OTC Product all over the

world -

Ketoprofen ketoplus cataplasma 60mg degenerative arthritis OTC Product all over the

world -

KD-fen Diclofenac 120mg Analgesia, anti-inflammatory OTC Product all over the world -

MedytoxNeuronox® Botulinum toxin

type A

Blepharospasm, Focalspasticity in pediatric

cerebral palsy,Glabellar Wrinkles

Biological Product

(Prescription medicine)

ROW, etc. -

Neuramis® Deep Hyaluronic acid Wrinkles Medical Device US, EU,etc. -

Samyang Biopharm

Genexol® Injection Paclitaxel Anti-cancer Prescription Medicine

EU, Middle-East,

Africa, South-

America, etc.

-

Genexol-PM®

Injection Paclitaxel Anti-cancer Prescription Medicine

EU, Russia, CSI,

Africa, South-

America, etc.

Cremophor free

formulation

Supplement

Supplement

5554

Samyang Biopharm

Nanoxel®-MInjection Docetaxel Anti-cancer Prescription

Medicine

EU, Middle-East,

Asia, Russia, CSI,

Africa, America, etc.

Tween-80 free

formulation

Rheumastop® Plaster

Diclofenac diethylamine NSAIDs OTC Medicine

EU, Middle-East,

Asia, Russia, CSI, Africa,

America, etc.

-

Rivastigmine Patch Rivastigmine Anti-ParkinsonAnti-Alzheimer

Prescription Medicine

EU, Middle-East,

Asia, Russia, CSI, Africa,

America, etc.

Lower API& same PK

Shin Poong Pharm

Hyal Inj. Sodium hyaluronate Rheumatic drugs Prescription Medicine world wide -

Hyal Forte Inj. Sodium hyaluronate Rheumatic drugs Prescription Medicine world wide -

Varodipine Tab. Amlodipine besylate Anti-hypertension Prescription Medicine world wide -

Hivix Tab. Clopidogrel bisulfate Anti-thrombotic Prescription Medicine world wide -

Losarcin Tab. Losartan potassium Anti-hypertension Prescription Medicine world wide -

SK chemicals

Esomeprazole capsule

Esomperazole free base Anti-ulcer Prescription

medicine EU -

Rivastigmine patch Rivastigmine Alzheimer’s disease Prescription medicine

Asia, Middle east

Already licensened in EU,US

and South Amreica

Albumin 20% Human Albumin HypoalbuminemiaPrescription

medicine (Blood product)

Asia, Middle east, South

America

Approved in several

Asian countries

Liv-Gamma (SN) Human Immunoglobulin Agammaglobulinemia & othersPrescription

medicine (Blood product)


America

Approved in several

Asian countries

Factor VIII Plasma derived Factor VIII Factor VIII deficiency

Prescription medicine

(Blood product)


America

Expected launch

date : Late Y2013

TRAST Piroxicam Osteoarthritis, Tenosynovitis, Myalgia, & others OTC product

Asia,South

America

Exporting to some Asian

countries

Joins Clematis mandshurica, & others. Osteoarthritis, Prescription

medicineAsia,South

America-

Mvix Mirodenafil Erectile Dysfunction Prescription medicine

Asia,South

America-

ST Pharm

- Zidovudine anti HIV/AIDS API US, EU etc. -

- Stavudine anti HIV/AIDS API US, EU etc. -

- Terizidone anti Tuberculosis API US, EU etc. -

- Clopidogrel Bisulfate Anti-coagulant API US, EU etc. -

- Atovastatin Calcium Anhydrous Metabolic disease API US, EU etc. -

Taejoon Pharm

Xalost Latanoprost Anti-glaucoma Prescription Medicine US -

Xalostplus Latanoprost plus Timolol maleate Anti-glaucoma Prescription

Medicine US -

Alpadine Olopatadine Conjunctivitis Prescription Medicine US,EU -

MC FREE Sodium CMC Dry eye Prescription Medicine US,EU -

Iobrix Iohexol Angiography Prescription Medicine US,EU,etc -

Supplement

Supplement

5756

2. Technology TransferCompany Category Indication Development Status Targeted

country NoteKorea OverseasAhngook Pharm

Herbal Respiratory(Relief of cough) Launched Preclinical Global -

Small molecule Respiratory(Relief of cough) Launched Preclinical Global except EU -

BCWORLD Pharm

Biologic Cancer Preclinical - US/EU -

Biologic Cancer Preclinical - US/EU -

small molecule hyperlipidemia Preclinical - US/EU -

small molecule Schizophrenia Preclinical - US/EU -

BioneersiRNA drug Solid cancer Preclinical Preclinical US, EU -

siRNA drug COPD(chronic obstructive pulmonary disease) Preclinical Preclinical US, EU, CN -

Boryung Pharm New chemical Entity Hypertension Launching Launching Global -

Bukwang Pharm

Small Molecule Cancer Phase 1/2a Phase 1/2a EU, Japan -

Nucleoside Hepatitis B virus Launched LaunchedNDA

South America, EU -

Chong Kun Dang

Small molecule Camtobell Cancer Launching - China, Taiwan, Macau

Small molecule CKD-501 Diabetes Pre-registration - Worldwide

Small molecule CKD-516 Cancer Launching - Worldwide

Small molecule CKD-581 Cancer Launching - Worldwide

Biosimilar CKD-11101 Anemia Phase 1 - Worldwide

Vaccine -Human

Papillomavirus (HPV) Vaccine

Preclinical - China

CJ Cheiljedang

Small molecule GERD Phase 1 Phase 1 China -

Small molecule Diabetes Phase III n/a China, SE Asia -

CrystalGenomics

small molecule Osteoarthritis(Inflammation, Pain)

CompletedPhase IIb - US, EU, China,

Japan, etc -

small molecule MRSA, VRSA infection - Phase IIa US, EU, China, Japan, etc -

small molecule Cancer Phase I(MAD) - US, EU, China, Japan, etc -

Dae Hwa Pharm

Mucous membrane adsorptive composition which enables poorly soluble compounds to

solubilize.Cancer Phase 3 - US, EU, etc. -

Manufacturing method of solubilize composition of paclitaxel Cancer Phase 3 - US, EU, etc. -

Percutaneous absorption product including diclofenac Analgesic Phase 3 - US, EU, etc. -

Manufacturing method of voglibose Diabetes Launching - US, EU, etc. -

Composition of percutaneous absorption including Tulobuterol Respiratory Launching - US, EU, etc. -

Daewon Pharm

small molecule Rheumatoid Arthritis Launching - - -

small molecule antitussive Launching - - -

small molecule appetite stimulant Phase 1 - - -

Daewoong Pharm

Small molecule Neuropathic pain Phase 2 - Worldwide -

Small molecule Alzheimer’s disease Phase1 - Worldwide -

Small molecule Fungal Infection Preclinical - Worldwide -

Biologic Cancer Phase1 Completed - Worldwide -

Biologic/Medical Device

Spine and Oromaxillofacial(BMP-2)

Clinical Trials Completed - Worldwide -

Dong Hwa Pharm Qunolones-Antibiotic Antibiotics Phase 2

completedPhase 1

completedUS, EU, JP,

CN, RU -

Dong-A Pharm

API Cancer Launching - EU, etc. -

API Erectile dysfunction Launching Launching EU, etc. -

Hanlim Pharm

Small molecule Age related Macular Degeneration Preclnical - USA

EU -

IMD Osteoarthritis Phase 2 -USA, EUEast Asia

South America-

Supplement

Supplement

5756

Hanlim Pharm

IMD Hypertension Phase 1 -USA, EUEast Asia

South America-

IMD Perennial allergic rhinitis Approval -Japan, EUEast Asia

South America-

Herbal Asthma Preclinical - USAEU -

Kwang dong Pharm Oral disintegration film Treatment of erectile

dysfunction Launching all over the world -

LG Life Sciences

Small molecule Diabetes Launching Phase 3 Worldwide DPP IV inhibitor

Biologics Rheumatoid arthritis Preclinical N/A Worldwide Antibodybiosimilar

Small molecule Myocardial infarction Phase 1 N/A Worldwide

Small molecule Gout Phase 1 N/A Worldwide XO inhibitor

Small molecule Atherothrombosis Phase 1 N/A Worldwide P2Y12 inhibitor

Medytox

Biologics(1)(Botulinum toxin product) Glabellar Wrinkles, etc. - phase 2 EU/US License

Out

Biologics(2)(Botulinum toxin product) Glabellar Wrinkles, etc. phase 1 - EU/US License

Out

Samyang Biopharm

polymer-basedparenteral DDS tech. Anti-cancer launching Ph 2 US, EU Solubility

enhancing

polymer-basedparenteral DDS tech. Anti-cancer Ph 1 (completed) Preclinical US, EU

Solubilityenhancing,Sustained

release

TDS tech. Neuropathic pain Ph 2 (completed) Preclinical US, EU Lower API& same PK

TDS tech. Severe pain Ph 1 (completed) Preclinical US, EULaunch

expectedin 2012

Oral DDS tech. - Preclinical Preclinical US, EUOral BA

enhancingtechnology

Shin Poong Pharm

SP-8203 Anti-stroke Preclinical Preclinical world wideSupported by Ministry of Knowledge Economy

Medicurtain® Anti-adhension Launched Preclinical world wideSupported by Ministry of Knowledge Economy

SP5M001 Osteo-arthrosis Preclinical Preclinical world wide -

SP5V003 Dermal filler Preclinical Preclinical world wide -

KR35454 Osteoporosis Preclinical Preclinical world wide -

SK Biopharm

Formulation Seizure, anxiety - Pre-NDA meeting

Japan, South Asia (India,

Malaysia, the Philippines etc.)

-

Small molecule Sleep awake - P2b start (4Q) Korea, China, Japan, South Asia -

Small molecule Seizure, neuropathic pain - P2b (on-going) Japan, EU -Small molecule Neuropathic pain - P2a (on-going) Japan, EU -

SK Chemicals

ALK5 inhibitor Fibrotic disease - Preclinical US, EU, Japan -11ß-HSD1 inhibitor Diabetes, Obesity - Preclinical US, EU, Japan -

GnRH antagonist endometriosis, uterine

myoma, BPH, and breast/prostate cancers.

- Preclinical US, EU, Japan -

HMP302 Alzheimer’s disease Phase III - US, EU Botanical originSK910 (Anastrozole depot injection) Breast cancer Preclinical - US, EU -

Yuhan Corporation

IMD Otitis media Preclinical - US, EU, etc -small molecule GERD Phase 2, 3 Phase 1 (US) US, EU, etc -small molecule IBS Phase 1 - US, EU, etc -small molecule Arteriosclerosis Screening - US, EU, etc -small molecule Diabetes Screening - US, EU, etc -

Supplement

Supplement

5958

3. International Quality Standard Certification Company Product name Active Ingredient dosage form Indication International

certification Note

Ahngook Pharm

Synatura syrupDried Ivy leaf ext. 262.5mg + Coptis Rhizome Butanol Dried

ext. 87.5mg among 100mlSyrup

Relief of cough and sputum due to acute respiratory infection and chronic

inflammatory bronchitis

KGMP certification -

Anycough Cap. Theobromine 300mg Capsule

Relief of cough symptoms caused by postnasal drip, gastroesophageal reflux

disease, bronchiectasis and chronic bronchitis


Anytin SR Tab. Trimebutine maleate 300mg Tablet Relaxation of digestive system KGMP certification -

Xaltrin XL Tab. Alfuzosin HCl 10mg Tablet

Treatment of the functional symptoms of benign prostatic hypertrophy (BPH)

Adjuvant therapy for catheter in acute urinary retention related to BPH


Anyfen syrup Dexibuprofen 12mg among 1mL Syrup Fever by acute respiratory infection KGMP

certification -

Boryung Pharm DOXORUBICIN DOXORUBICIN API ONCOLOGY EU GMP scheduled

Chong Kun

Dang

Sepirom Ceftriaxone Sodium hydrate Injection Antibiotics PMDA certification -

Rasenazolin Cefazolin sodium Injection Antibiotics PMDA certification -

Pengood Bacampicillin hydrochloride Tablet Antibiotics PMDA certification -

Kmoxilin Amoxicillin/Potassium clavulanate Tablet Antibiotics Anvisa

certification -

CJ Cheiljedang

Cefotaxime inj. Cefotaxime Inj. Infection Japan DMF -

Ceftazidime inj. Cephtazidime Inj. Infection Japan DMF -

Ceftriaxone inj. Ceftriaxone Inj. Infection Japan DMF -

Dong Hwa Pharm - Pantoprazole(API) - Anti-ulcerants EU GMP

certification -

Dong-A Pharm

Closerin Cycloserine Capsule Anti TB WHO GMP certification -

- Zidovudine API HIV cGMP Certification -

Kuhnil Pharm

- - Freeze-dried Inj. - EU GMPJapan AFM

(Accreditation certificate of Foreign drug

Manufacturer) Registration

-

- - Solution for Inj. - -

- - Prefilled syringe - -

LG Life Sciences

Factive Gemcifloxacin Tablet Antibiotics FDA GMP certification -

hGH human Somatropin Injection Growth hormone deficiency

FDA GMP certification

EU GMP certification

-

Euvax B Hepatits B vaccine Injection Hepatits B vaccine

WHO GMP certification

EU GMP certification

-

Euforvac-Hib DTP-HepB-Hib vaccine Injection DTP-HepB-Hib vaccine WHO GMP certification -

Hyruan plus Hyaluronic acid Injection Joint arthritis CE certification -

Supplement

Supplement

5958

MedytoxBiologics(1)

(Botulinum toxin product)

Botulinum toxin type A

Vial (lyophilized)

Glabellar Wrinkles, etc. cGMP & EU GMP

Under contruction

and completion

in 2013.

Samyang Biopharm

Rheumastop Diclofenac diethylamine Plaster NSAIDs Australia (TGA)

GMP certification -

Anti-cancer Injection

Anti-cancer Injection Injection Anti-cancer Iran (MOH)

GMP certification -

Genexol Paclitaxel Injection Anti-cancer EU GMP certification (DE)

Genexol Paclitaxel Injection Anti-cancer Hungary (NIP)GMP certification -

Genexol Paclitaxel Injection Anti-cancer Egyptian (HMA)GMP certification -

Shin Poong Pharm PYRAMAX® Pyronaridine & Artesunate Tablet Anti-malaria EU GMP

Certification -

SK Chemicals

Omeprazole tablet Omeprazole free base Tablet Antiulcer EU GMP certification -

Esomeprazole capsule Esomeprazole free base Capsule Antiulcer EU GMP

certification -

Rivastigmine patch Rivastigmine free base Transdermal

patch Agent for Alzheimer’s disease EU GMP certification -

ST Pharm

- Zidovudine API anti HIV/AIDS US FDA GMP-API -

- Zidovudine API anti HIV/AIDS WHO/EDQM GMP-API -

- Zidovudine API anti HIV/AIDS PMDA GMP-API -

- Zidovudine API anti HIV/AIDS TGA GMP-API -

- Zidovudine API anti HIV/AIDS ANVISA GMP-API -

Taejoon Pharm

Xalost Latanoprost Solution Anti-glaucoma EU GMP certification -

Xalostplus Latanoprost plus Timolol maleate Solution Anti-glaucoma EU GMP

certification -

korea innovative pharmaceutical company directory book

Documents

Transcript of korea innovative pharmaceutical company directory book